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TO IDENTIFY THE CHANGES IN THE HAEMODYNAMICS 
IN PATIENTS WITH PRE-ECLAMPSIA USING BRAIN 
NATRIURETIC PEPTIDE AND DOPPLER STUDIES 
ABSTRACT 
AIM: 
To determine the haemodynamic changes in pre-eclampsia by using 
echocardiography and cardiovascular markers i.e. Brain Natriuretic Peptide (BNP); 
and relating these changes to perinatal outcomes. 
MATERIAL AND METHODS: 
A prospective study was conducted at a large regional hospital in Durban, KwaZulu 
Natal. One hundred and fifteen primiparous patients were studied; 63 were 
normotensive pregnancies and 52 were pre-eclamptics. Patients were matched for 
age and gestational age. Study participants were examined during pregnancy, labour 
and within the puerperium. Transthoracic echocardiography, tissue Doppler imaging, 
umbilical artery Doppler, and laboratory investigations were performed. The ratio of 
the mitral inflow (E) to the early diastolic tissue Doppler velocity (Ea) was measured 
as a marker of the left ventricular filling pressure. 
RESULTS:   
BNP levels were significantly increased in the antepartum (23.8 (2 - 184.1) vs 6.0 (0.5 
- 45.2) pmol/L; p<0.001) and during labour (15 (1.8-206.4) vs 8.7 (1.9 -24.8) pmol/L; 
p=0.01) in the pre-eclamptic group when compared to the normotensive 
pregnancies. In the postpartum period, median BNP levels were 4.2 (1.7-51.4) and 
5.95 (2.2-38.7) pmol/L in the pre-eclamptic and normotensive groups, respectively. 
There was no statistically significant difference in the tissue Doppler E/Ea between 
the pre-eclamptic when compared to the normotensive group of patients (11.02 ± 
5.6 vs 9.16 ± 2.6; p=0.058).  The caesarean section rate was 47% in the pre-eclamptic 
group and 32% in the normotensive group. Eight subjects were lost to follow-up, 
therefore no inference could be made from this data. There were 2 stillbirths in the 
pre-eclamptic group, none in the normotensive group.  




In pregnancies complicated by pre-eclampsia, changes in the haemodynamic state 
are accompanied by raised blood levels of BNP in comparison to normotensive 
pregnancies. These revert to baseline values in the puerperium.  







HYPERTENSIVE DISORDERS OF PREGNANCY 
Hypertensive disorders of pregnancy complicates approximately 10-16% of 
pregnancies and is one of the leading cause of maternal, fetal and neonatal 
morbidity and mortality worldwide (1, 2). A recent population-based study estimates 
that hypertensive disorders of pregnancy affect 12% of pregnant women in Durban, 
South Africa (SA) (3). Hypertensive disorders of pregnancy accounts for about 9% of 
maternal deaths in Africa and Asia, and about 25% of maternal deaths in Latin 
America and the Caribbean. The maternal deaths are mainly due to pre-eclampsia 
and eclampsia (4). According to the recent National Confidential Enquiry into 
Maternal Deaths (NCCEMD) report in SA, which assessed avoidable factors and 
missed opportunities in deaths that occurred at health facilities from 1 January 2005 
until 31 December 2007, approximately 15% of all deaths were due to hypertension 
and its complications. Hypertensive disorders of pregnancy were the commonest 
direct cause of maternal deaths in SA. It was found that over one half (52.7%) of all 
hypertensive-related deaths were avoidable. The highest number of deaths (21.2%) 
occurred in the province of Kwa-Zulu-Natal. Furthermore cardiac disease accounted 
for 2.2% of all deaths (5).  
Hypertensive disorders of pregnancy have been classified by The National High Blood 
Pressure Education Program of the National Health Lung and blood institution 
(NHLBI) into the following categories: gestational hypertension, chronic 
hypertension, PE and superimposed PE (6). Gestational hypertension is a working 
definition used when an elevated blood pressure (BP) (systolic BP >/= 140mmHg and 
diastolic >/= 90mmHg) is first detected after the twentieth week of pregnancy (in the 
absence of proteinuria) and returns to normal in the peuperium. Women diagnosed 
with gestational hypertension may eventually fulfill diagnostic criteria for PE if 
proteinuria subsequently develops. In the absence of proteinuria, chronic 
hypertension is diagnosed when elevated blood pressures are present before 20 
weeks gestation and remain elevated postpartum. Pre-eclampsia is defined as the 
presence of hypertension, and proteinuria exceeding 0.3 g/day after the twentieth 
week of pregnancy in a previously normotensive woman. PE occurs in 2-5% of 
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pregnancies worldwide but it complicates up to 10% of pregnancies in developing 
countries where emergency care is often inadequate or lacking (6).   
 
PRE-ECLAMPSIA 
The cause of PE remains unclear. Pre-eclampsia is characterised by the new onset of 
hypertension (systolic and diastolic blood pressure of ≥ 140 and 90 mmHg 
respectively on two occasions at least 6 hours apart) with proteinuria (protein 
excretion of ≥ 300mg in a 24 hour urine collection, or a dipstick of ≥ 2+) that 
develops after 20 weeks gestation in a previously normotensive woman (7, 8).  The 
cure is delivery of placenta. Known maternal characteristics such as obesity, ethnicity 
(black race), diabetes, collagen vascular disease, multiple pregnancies, previous 
episodes of PE, thrombophilias, molar pregnancy and extremes of age (<20 or >40 
years) increase the risk for PE. Women with chronic hypertension have a 15–25% 
increased risk of developing superimposed PE (9). The prognosis for mum and baby 
depends on the severity of the pre-eclampsia. In mild disease, there is a good 
prognosis. In severe disease, complications include abruption placenta, eclampsia, 
renal and liver disease, disturbances of haemostasis and the HELLP syndrome. A 
higher incidence of pre-eclampsia has been found among women who conceive with 
assisted reproduction techniques, nulliparous women, and in women with 
autoimmune conditions demonstrating the probable influence of an inexperienced 
maternal immune system (10, 11). Women with pre-existing metabolic, vascular or 
renal disease are at increased risk for superimposed PE (12, 13). This is possibly due 
to their increased sensitivity to the physiological changes of pregnancy. 
Identifying “at-risk” women is important because modern obstetric care places 
emphasis upon the primary care setting for expectant women. A marker which 
identifies high-risk women would allow for closer supervision in secondary care. Such 
a marker would also facilitate recruitment for trials of potential therapeutic agents, 
for accurate diagnosis, and for timely intervention whenever problems develop.  
 
PATHOPHYSIOLOGY OF PRE-ECLAMPSIA 
The placenta is considered central in the pathogenesis of PE (14). This is known to be 
the case because PE occurs only in pregnancy and resolves after delivery of the 
placenta. Furthermore, it can occur in the absence of a viable fetus for example, in 
molar pregnancies (15).  
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The pathophysiology of PE it is believed to be multifactorial. The teaching has been 
that PE develops due to an immune maladaptation between the mother and the 
fetus. Poor placentation is considered the first step in the two-stage theory (16). 
Trophoblastic invasion of the maternal spiral arterioles occurs early in pregnancy and 
results in the formation of wide-bore vessels carrying maternal blood to the 
developing fetus.  Defective trophoblastic invasion, possibly due to genetic or 
immune mechanisms, results in the spiral arterioles remaining as narrow conduits. 
The result is tissue anoxia due to hypoperfusion (17). The consequence of the tissue 
anoxia is the release of apoptotic cells, trophoblastic debris and angiogenic factors 
that causes widespread vascular endothelial damage (18, 19). This leads to the 
second step of the disorder which is the development of maternal signs and 
symptoms affecting multiple systems of the body (20).  
BIOCHEMICAL MARKERS OF PRE-ECLAMPSIA 
The ideal marker would be non-invasive, cheap, with a high sensitivity and specificity 
and suitable for resource limited settings.  Based on the etiology of this life-
threatening pregnancy disorder, a major focus of research has recently been 
maternally expressed proteins and the identification of placental factors showing 
abnormal expression in pre-eclamptics placentas (21, 22). Their potential use for 
non-invasive early prediction or early detection would be invaluable. The availability 
of such markers could potentially improve surveillance of high risk patients and 
result in earlier referrals and better outcomes. The impact and cost of treating the 
complications of PE (e.g prolonged ICU admissions, etc) for both the family and the 
heath system could potentially be reduced.  
Misdiagnosis and failure to recognise warning symptoms is still an issue in our health 
care system owing partly to the multiple clinical symptoms associated with the 
syndrome (23). The availability a reliable biochemical indicator might thus help in 
making the clinical diagnosis. Biochemical markers would allow the classification of 
pre-eclamptic patients into categories based on their severity and this would direct 
the clinical management and improve the pregnancy outcomes (24). 
IDENTIFICATION OF NOVEL BIOMARKERS 
Although a number of promising biomarkers already exists, a lot of effort is being 
made to find novel candidates that bear a greater potential to identify women at risk 
for PE, in order to provide the best possible care for these mothers and children (25, 
26). Several approaches have been made (27, 28, 29). Microarrays screen the 
placental transcriptome for up- and down-regulated transcripts in pre-eclamptic 
samples and compare these to healthy controls. Comparative transcription analyses 
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have been performed by numerous groups (30, 31, 32). These groups were however, 
studying the molecular mechanisms of PE rather than potential biomarkers. The 
microarray based screening for RNA molecules in maternal circulation that are 
transcribed in placenta has been reported as a potential source for pregnancy 
related biomarkers (33, 34), including PE (35, 36). Gene experiments are being 
performed frequently due to the rapid evolution of the microarray technology. 
Another direction of research in the field of complex diseases is metabolomics.  It 
involves the analysis of endogenous and secreted metabolites in a biological system. 
The reports investigate the placental metabolome using varying oxygen tensions in 
the plasma of pre-eclamptic patients. It is suggested that this technology may bring 
new insights into placental function (37, 38). 
 
THE NATRIURETIC PEPTIDE SYSTEM 
Most of the molecular markers that have been described above relate to the 
pathogenesis of the PE process. The early sequelae in PE involve well documented 
haemodynamic changes which have been investigated and corrobated by invasive 
and non-invasive techniques. The naturetic peptide system, first discovered in the 
early 1980s to regulate salt and body fluid balance, has been shown to closely reflect 
fluid dynamics in the circulation (39).  
Human cardiocytes manufacture a family of structurally related peptide hormones 
that include atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide 
(BNP), and their metabolically associated peptides (40). Release of the natriuretic 
peptides is stimulated by haemodynamic stress, such as wall stretch, ventricular 
dilation, and increased pressures resulting from fluid overload. The natriuretic 
peptides have powerful natriuretic, diuretic, antimitotic, and vascular smooth muscle 
relaxing actions. The natriuretic peptides are antagonists for the sympathetic 
nervous system and the renin-angiotensin-aldosterone axis (41). 
BNP has emerged as a superior biomarker to ANP for clinical applications involving 
heart failure and left-ventricular dysfunction (42). In a study by Cowie and colleagues 
(43), BNP showed a greater predictive power as an indicator of heart failure when 
compared with either ANP or its metabolites. Contributing factors are BNP's longer 
half-life, activation at the gene level and greater quantity in left ventricular tissue. 
Also, BNP has a 2- to 3-fold more powerful natriuretic and blood pressure lowering 
effect compared to ANP (44). Thus in vitro diagnostics for BNP and associated 
metabolites have been the focus for clinical applications (45). 




BIOSYNTHESIS AND SECRETION OF BNP AND NT-proBNP  
Human BNP is derived from 134 amino-acid precursor termed pre-proBNP1-134. 
Haemodynamic stress activates cleavage of a 26-aa signal peptide sequence from 
the N-terminus of pre-proBNP1-134. The remaining proBNP1-108 prohormone is 
then cleaved by corin; the N-terminal pro-BNP1-76 (NT-proBNP) fragment and active 
32-peptide, C-terminal BNP77-108 (BNP) hormone are then released into the 
circulation. BNP and the metabolically inert NT-proBNP are released in a 1:1 molar 
ratio. 
The release and metabolism of BNP and NT-proBNP is a far more complicated 
process. The intact prohormone proBNP1-108 may be released into circulation and 
may cross-react with immunoassays for BNP and NT-proBNP. Also, N-terminal 
proBNP1-76 in blood may be comprised of numerous fragments and not a single 77 
amino-acid molecular entity. Furthermore, BNP appears be undergo metabolism 
following release into the circulation. Truncation of the 32-amino acid peptide at 
either the C-terminal or N-terminal arms to an inactive form of BNP has been 
reported (46).  
 
MECHANISM OF ACTION OF NATRIURETIC PEPTIDES 
The primary function of ANP and BNP is to regulate blood volume and pressure. 
Under high blood volume or pressure, ANP and BNP are released into the circulation. 
In target organs such as the kidneys and peripheral blood vessels, the peptides 
activate their receptor, natriuretic peptide receptor –A (NPR-A), and increase 
intracellular cGMP production. This leads to natriuresis, diuresis, and vasodilation 
resulting in the lowering of blood volume and pressure. ANP and BNP also suppress 
the renin angiotensin release, which is an additional mechanism to regulate vascular 
tone (47). The blood levels of BNP and NT-proBNP, reflect haemodynamic stress, and 
as such, may serve as a marker of early haemodynamic changes that accompany PE. 
 
HAEMODYNAMICS AND CARDIAC CHANGES IN PE 
During normal pregnancy, plasma volume increases steadily throughout the first two 
trimesters and reach a plateau at approximately 32 weeks gestation. In a singleton 
pregnancy at term, plasma volume is nearly 50% more than that seen in a non-
pregnant woman. Total peripheral vascular resistance decreases in normal 
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pregnancy, cardiac output increases, reaching a peak of 30-50% of the pre-
pregnancy level by the end of the 2nd trimester. There is usually no further increase 
(48). In patients with PE, there is a further rise in cardiac output as well as an 
increase in total peripheral resistance (49). 
There is evidence that cardiac function is altered in PE. Significant changes in the 
volume status and systemic resistance have been documented in patients with pre-
eclampsia. Left ventricular mass (and index) in PE patients is higher than 
normotensive patients and is associated with increased left ventricular wall 
thickness. There appears to be no difference in left ventricular diastolic filling rates 
between PE and normotensive patients (49).  A further significant increase in left 
ventricular end-systolic and end-diastolic volumes and reduction in contractile 
function has been found in PE women. Under these conditions, changes in volume 
loading may affect ventricular function. There are limited data available on the 
changes in cardiac structure and function during PE. Most studies focus on changes 
in normotensive patients (50). A study found that there was reduced cardiac 
function in pregnancies complicated by pre-eclamptic IUGR when compared to 
normotensive IUGR pregnancies (51). This was due to reduced intrinsic contractility 
and reduced diastolic filling. Some markers of the changes in diastolic filling would 
help to understand the haemodynamic changes of PE. Left ventricular diastolic filling 
may precede changes in systolic function. Therefore, assessment of diastolic function 
may provide an early marker of PE.  
 
INVESTIGATIVE EVALUATION OF MATERNAL HAEMODYNAMICS 
Several diagnostic investigations have been used to evaluate the cardiac changes 
that occur in PE, but because of the physiological changes seen even in normal 
pregnancies (Table 1), interpretation of these findings is often difficult. 
Page | 17  
 
 
Table 1: Chest X Ray and Electrographic Changes in normal Pregnancy 
Chest X-ray Electrocardiogram 
Increased cardiothoracic ratio  ST segment and T wave changes  
Straightened left heart border Atrial and ventricular ectopics  
Increased pulmonary vascular markings Leftward shift of QRS axis  
Small pleural effusions (early post 
partum period) 
Small Q wave,inverted T wave in lead lll 
 
TISSUE DOPPLER ECHOCARDIOGRAPHY 
What is required is a sensitive measure of the cardiac changes that occur during PE, 
which may easily be measured non-invasively. Until recently most of the non-
invasive studies of the hemodynamic changes of PE have employed 
echocardiography with the focus being on cardiac dimensions and systolic function. 
Tissue Doppler imaging of the heart is a technique that has enabled the evaluation of 
changes in ventricular filling at a much earlier stage than can be detected by 
conventional echocardiography. This technique measures the frequency of 
ultrasound returning from the moving myocardium to estimate the velocity of the 
myocardial wall. Isaaz et al (1989) were the first to describe the clinical applications 
of tissue Doppler in cardiac disease, demonstrating that low myocardial velocities at 
the posterior mitral annulus correlated with abnormal posterior wall motion on left 
ventricular angiography (52). Gulati et al (1996) demonstrated that tissue Doppler 
systolic mitral annular velocities correlated with global left ventricular ejection 
fraction as assessed by radionuclide ventriculography (53).  Diastolic tissue Doppler 
velocities reflect myocardial relaxation, and in combination with conventional 
Doppler measurements, ratios (transmitral early diastolic velocity / mitral annular 
early diastolic velocity (E/Ea) have developed to non-invasively estimate left 
ventricular filling pressure. It has been shown that Tissue Doppler derived Ea 
correlated with the invasively measured left ventricular time constant of relation 
(Tau), establishing Ea as a relatively load independent measure of myocardial 
relaxation in patients with cardiac disease (54).  
Echocardiography is a good diagnostic tool as it allows for the structural as well as 
functional assessment of the heart. Furthermore the cardiovascular changes that 
have been documented appear to coincide with increases in plasma BNP and have 
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been observed to be linearly related to the left ventricular structural and functional 
changes observed in patients with PE (49).  
 
THE EVALUATION OF VENTRICULAR FUNCTION  
Our study was designed to evaluate BNP changes in PE as a measure of ventricular 
function. As previously mentioned, BNP and ANP are polypeptide neurohormones 
synthesized by cardiac atrial and ventricular myocyes in response to stretch (55). 
They have a regulatory and modulatory role in the cardiovascular system. They are 
secreted as prohormones, proANP and proBNP. They are then split into equimolar 
amounts of active ANP and BNP, and inactive amino-terminal fragments NT-proANP 
and NT-proBNP (56). BNP levels reflect long-term intravascular volume status. It 
shows less affinity for clearance receptors and therefore has a longer half life than 
ANP. ANP is more dependent on atrial filling volume than filling pressure and is 
rarely measured in clinical practise. BNP and NT-proBNP are more commonly 
measured, often interchangeable, based on clinician’s preference and laboratory 
availability (57). There is evidence however, that NT-proBNP measurement is 
superior in detecting mild systolic or diastolic heart failure or asymptomatic left 
ventricular dysfunction (LVD) (58). There is fast synthesis and release into the blood 
by myocardial stretch which is increased in LVD. Left ventricular stretch activates 
neuronal and hormonal pathways that results in BNP being secreted directly into the 
blood during ventricular dilatation. Increased plasma levels of BNP have been found 
in patients with LVD from various causes. BNP has a high sensitivity, specificity and 
predictive value for LVD and is an approved marker for the diagnosis of congestive 
heart failure in patients with dyspnoea in an acute care setting (59). During normal 
pregnancies, haemodynamic changes do not place significant stress on the heart. 
However, increased ANP and BNP levels of statistical significance were found in 
patients with PE as compared to normotensive pregnant patients. A study which 
evaluated maternal, umbilical plasma and amniotic fluid BNP and ANP levels in 
nineteen normotensive pregnant women and thirty five pre-eclamptic patients 
suggested that increased ANP and BNP levels were a sequel of PE pathophysiology 
and did not play an etiological role in PE (60). Another study looked at the trends in 
BNP levels during pregnancy. BNP blood levels were taken during the 1st, 2nd and 
3rd trimester in normotensive as well as in patients with PE. In normotensive 
pregnancies, median BNP levels are < 20pg/ml and stable throughout gestation. An 
increase in BNP levels in pregnancies complicated by mild PE and an even higher 
increase in severe pre-eclamptics was found. This may reflect ventricular strain and/ 
or subclinical cardiac dysfunction associated with pre-eclampsia (61). In a study 
Page | 19  
 
 
investigating the role of BNP in the circulation of patients with pregnancy induced 
hypertension, they found that BNP and ANP participate in maintaining homeostasis 
of the maternal circulation. This cross-sectional study looked at thirty six normal 
pregnancies and compared levels of BNP and ANP to seventeen women with 
pregnancy induced hypertension. They found statistically significant increased levels 
of BNP and ANP in patients with pregnancy induced hypertension. In patients with 
severe pregnancy induced hypertension, an eight-fold increase in BNP levels were 
found. There was a positive correlation between the plasma BNP levels and the 
mean arterial blood pressure (r=0.62, P<0.001) (62). Numerous studies have 
confirmed the definite increase in BNP levels in patients with PE (63, 64). In a study 
looking at the natriuretic peptides and PE, it was found that the high BNP 
concentrations found in pre-eclampsia reflect cardiac strain caused by high afterload 
(64). In a review of the charts of fifteen obstetric patients who presented with acute 
dyspnoea, seven of them had PE with elevated BNP levels. This correlated with acute 
ventricular overload and they responded well to volume management and diuresis. 
In two patients, markedly elevated serum BNP levels and significant left ventricular 
dysfunction was found that was not apparent by standard clinical evaluation. It was 
thus concluded that serum BNP levels provided valuable information that could be 
used in the management of obstetric patients with acute dyspnoea and may assist in 
identifying patients with cardiac dysfunction that might have been otherwise missed 
on clinical evaluation (65).  
 
TIMING OF TESTING 
So, if serum BNP is activated during pregnancies complicated by PE, the crucial 
question is “when is the optimal time to test these levels”; and “when do they return 
to normal?” In a study comparing proBNP levels in pre-eclamptic versus 
normotensive obstetric patients antenatally, and then later in the puerperium, the 
proBNP level in the pre-eclamptic group showed a seven-fold increase to that of the 
control group (p > 0.05). Of note is that in the puerperium, these levels normalised 
(66). In the non-pregnant situation, a study by Bayes-Genis et al., found that there 
was a good association between the New York Heart Association functional class and 
NT pro-BNP concentrations; NT pro-BNP concentrations in the emergency rooms did 
not significantly differ from those after 24 hours; NT pro-BNP concentrations on day 
7 did not differ from that at 6 or 12 months and could be considered as the basal 
stable level for that particular patient (67).  
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We know that there are dramatic changes in circulating volume in the perinatal 
period which would influence BNP levels in relation to labour and uterine 
contractions. Not much is known about changes in BNP on an hour to hour basis. 
Vasoactive hormones are said to play an important role in the pathogenesis of pre-
ecalmpsia thus linking placental hypoperfusion with hypertension, systemic disease 
and proteinuria. In a study evaluating the diurnal patterns of vasoactive hormones in 
PE and comparing these to a normotensive comparable control group, it was found 
that in the control group there was diurnal variations (blood samples were taken 
every 2 hours over a 25 hr period) in serum BNP levels amongst others. The BNP 
concentrations in the PE group tended to be higher throughout the 25 hours but had 
blunting of the normal diurnal variation (68). Although this study did show certain 
trends, in clinical practise it is difficult for serum sampling to be done at exactly the 
same time in our patients. 
 
ULTRASOUND AND DOPPLER STUDIES 
Ultrasound allows for a detailed, painless and safe analysis of the placenta and fetus. 
Numerous investigative modalities have been used by researcher’s e.g X-rays by 
Panigel demonstrating placental maternal blood jet lags, Magnetic Resonance 
Imaging, 2-dimensional grey-scale ultrasound, colour imaging and now 3-
dimensional ultrasound imaging (69). Several medical disorders of the pregnant 
woman or her fetus begin or end in the placenta. Examples of these include PE, 
IUGR, triploidy, etc.  Ultrasound is the optimal investigation method because of the 
benefits mentioned above as well as the fact that it allows for placental structural 
and functional assessment. Three dimensional ultrasound permits evaluation of the 
placenta in several planes, more precise depiction of internal vasculature and a more 
accurate assessment of volume.  
Pre-eclamptic vascular changes are seen relatively early in pregnancy. At the level of 
the uterine circulation, significant haemodynamic changes have been documented. 
Harrington et al confirmed that the development of PE was associated with failure to 
modify the uterine circulation in early pregnancy as shown by abnormal Doppler 
values done between 12-16 weeks gestation (70). In another study investigating the 
vascular mechanical properties and endothelial function in PE with special reference 
to bilateral uterine artery notch (bilateral uterine artery notch is associated with 
ischaemic pathology), it was found that a significant number of placentas in the 
group with PE did not show noteable ischaemic or other morphological changes that 
could explain the role of the placenta in the development of PE. Women with PE 
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showed signs of endothelial dysfunction significantly more pronounced in women 
with the bilateral uterine artery notch (71). 
Inadequate placental perfusion has lead to the use of Doppler ultrasonography to 
assess the velocity of the blood flow in the uterine arteries. A persistence of an early 
diastolic notch after 24 weeks of gestation or abnormal flow velocity ratios has been 
associated with inadequate trophoblast invasion. Pregnancies associated with an 
abnormal uterine Doppler after 24 weeks of gestation (high pulsatility index and/or 
presence of an early diastolic notch) are associated with a more than six fold 
increase in the rate of pre-eclampsia (72). 
Among high-risk patients with a previous PE, Doppler ultrasound of the uterine 
arteries has an excellent negative predictive value, thus it is an important tool in 
patient management and care which is of paramount benefit for patients with PE in 
a previous pregnancy. A systematic review evaluated the use of Doppler 
ultrasonography in PE. A total of 74 studies were included. Of these studies, 69 were 
cohorts, 3 were randomized controlled trials and 2 were case-control studies. These 
studies involved a total of 79547 patients, 2498 of whom developed PE. The authors 
showed that Doppler ultrasonography of the uterine arteries were more accurate in 
the second trimester than in the first trimester. The most predictive measurement of 
the Doppler ultrasonography to predict PE was shown to be the pulsatility index 
(alone or in combination with a persistent notching after 24 weeks of pregnancy) 
(73). 
A study showed that the combined measurement of uterine perfusion in the second 
trimester and analysis of angiogenic markers have a high detection rate for pre-
eclampsia (74). However, data does not support the use of Doppler ultrasonography 
for routine screening of low risk patients for PE. A multicentric study involving nine 
hundred and sixteen low risk pregnancies were followed up with end points being 
PIH, low birth weight for gestational age, small for gestational age with abnormal 
outcome and PIH requiring delivery. The study was blinded. Umbilical and uterine 
artery Dopplers were performed nineteen to twenty four weeks gestation and at 
twenty six to thirty one weeks gestation. This study found the positive predictive 
value to be low. It did, however, identify the severe forms of PIH and small for 
gestational age fetus’ in mid pregnancy but could not be used as a screening tool in a 
low risk population where the prevalence of the disease is low (75). Doppler 
velocimetry of the umbilical cord has been found to be a more specific and sensitive 
method of fetal surveillance than cardiotography. It is a fast and convenient method 
for monitoring fetal well being in high risk pregnancies (76). 
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Ultrasound and Umbilical Artery Dopplers have also been well studied and their 
importance in predicting fetal outcomes is well established (77, 78). The use of 
Doppler studies even in mild PE has been shown to be essential and prompt 
response to abnormalities validated as shown in the following case report. A 
pregnant woman with mild PE and severe growth restriction, with reverse end-
diastolic flow velocity detected on uterine arteries by colour Doppler was managed 
expectantly. Follow up Doppler studies of the internal iliac and umbilical arteries also 
showed reverse flow. This fetus died two weeks after initial abnormality detected 
(79).   
Another study estimated systolic/diastolic ratios in a low risk population to see if this 
could be used as a screening tool. It was found not to be useful as the positive 
predictive value was calculated to be between zero and five percent. It was also 
found to be of no clinical use in predicting IUGR in this population group. One 
thousand six hundred and sixty five Doppler examinations were performed on five 
hundred and sixty five women in this study. Dopplers were performed at 27-31, 32-
36 and 37-42 weeks gestation. Low dose aspirin (60mg) was also used in this double 
blinded prevention trial from twenty four weeks gestation. Aspirin did not affect the 
relation between the Doppler indices and outcomes using the logistic regression 
model (80). In our study, we looked at the Resistance Index (RI) in patients in the 
third trimester.  
“Reverse Flow” as a sonographic finding, indicates the appearance of retrograde 
blood flow in the diastolic part of the cardiac cycle and is an indicator of 
deterioration of the fetal condition (81). Reversed end-diastolic flow velocity is well 
known to be an ominous finding. A study conducted on thirty patients during the 
third trimester with reversed end diastolic flow found a perinatal mortality rate of 
fifty percent. All newborns were admitted to the NICU. Statistically significant 
complications included caesarean sections, fetal acidosis and small for gestational 
age babies (82). It is thus imperitive that intensive and frequent surveillance be 
carried out and prompt aggressive management plans be implemented in an 
attempt to alleviate these devastating outcomes when reverse end-diastolic flow is 
identified. 
Abnormal Doppler umbilical artery waveform is a strong predictor of perinatal 
mortality and is associated with a poor perinatal outome. The study, conducted over  
2 year period, included 43 patients with severe PE. Of these, twenty-two (52%) had 
abnormal Doppler umbilical pulsatility index. The abnormalities included: positive 
end diastolic velocities with elevated pulsatility index values (13 patients/ 59%), 
absent end diastolic velocometries (7 patients/ 32%) and reversed flow (2 patients/ 
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9%). There were 6 perinatal deaths in this group with abnormal umbilical artery 
Dopplers, two in the reversed flow (100%), two in the absent flow (28%) and 2 in the 
positive end diastolic flow (15%). There were no perinatal deaths in the group with 
normal umbilical Doppler waveform. Of note is that neonates with abnormal 
pulsatility index had lower birth weights, lower APGAR score at 5 minutes, higher 
admission rates to the neonatal intensive care units and significant neonatal 
morbidity as compared to those with normal velocimetry (p<0.05) (83).  
Interestingly, in a study looking at the independent contribution of absent or 
reversed end-diastolic umbilical artery Doppler flow in the prediction of adverse 
neonatal outcomes, only an increased frequency of hypoglycaemia (OR 1.7) and 
polycythemia (OR 1.7) were found whereas other negative outcomes could be 
explained by prematurity and IUGR. Two hundred and seventy pregnancies 
complicated by PE with either absent or reversed flow where followed up. Other 
outcomes included low APGAR scores, thrombocytopaenia, jaundice, neonatal 
mortalities, etc. Gestational age, oligohydramnios and IUGR were controlled for (84).  
An abnormal Doppler result usually preceeds the appearance of an abnormal 
biophysical profile. Fetal well being by weekly assessing umbilical artery Dopplers 
and biophysical profiles were investigated in patients with pre-eclampsia in their 
third trimester. It was found that thirty eight percent of patients had an abnormal 
Doppler on the last evaluation before delivery. In this group, significantly higher 
blood pressures and serum uric acid were recorded, lower platelet counts, higher 
incidence of IUGR, lower APGAR score at five minutes, a higher incidence of perinatal 
deaths and higher operative delivery rates. Abnormal Doppler results clearly help to 
identify fetus at risk requiring intensive surveillance (85).  
 
TYPES OF DOPPLER STUDIES 
So which Doppler examination is the best in evaluating underperfusion and should 
be used in the management of patients with PE? Numerous sites have been 
evaluated with often contradicting results. Intraplacental villous artery Doppler 
measurements have been found to be of no value in the clinical management of 
patients with severe pre-eclampsia (86). A study looking at forty three patients; 
twenty normotensive and twenty three with severe PE found that intraplacental 
villous flow were within normal limits even in patients with abnormally high 
umbilical artery resistance indices. There was no difference in the intraplacental 
villous artery resistance indices between the two groups. Failure to detect villous 
artery Doppler flow signals was associated with fetal compromise (86). 
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Whether uterine artery Doppler, umbilical artery Doppler or both should be 
examined in high risk pregnancies has been a topic of much debate with conflicting 
results. A study examined two hundred and eighty women with singleton 
pregnancies in the third trimester. While blood flow in the cerebral and umbilical 
arteries remained unchanged, Doppler indices from the main uterine branches 
showed increased resistance. This study concluded that increased uterine artery 
resistance is an early indicator of increased risk to the fetus when compared with 
umbilical and fetal cerebral artery Dopplers (87).  Another study involving one 
hundred and forty two patients with intra-uterine growth restriction (birth weight 
<10th percentile) and/ or PE/ HELLP Syndrome, was conducted where they examined 
the umbilical artery Doppler and bilateral uterine artery Dopplers. Patients were 
divided into six groups based on Doppler findings i.e. uterine artery unilaterally/ 
bilaterally normal/ pathological and umbilical artery normal/ pathologic. The median 
birth weight, gestational age at delivery and frequency of occurrence of 
complications were calculated. The birth weight and gestational age at delivery were 
significantly lower where there was a pathologic result in all three vessels. PE/ HELLP 
Syndrome were found in only six percent of patients who had pathological findings 
in the umbilical artery Doppler. However, ninety percent of patients who had 
pathologic findings on uterine artery Doppler developed PE/ HELLP syndrome. The 
umbilical artery Doppler was normal in twenty eight percent of this high risk group. 
Without performing the uterine artery Dopplers, the impaired placental 
haemodynamics would have been missed. The authors advised examination of both 
uterine and umbilical artery Doppler as an important tool in assessing placental 
performance and high risk groups (88). In another study confirming the importance 
of both uterine and umbilical artery Doppler examinations in predicting adverse 
outcomes in pregnancies complicated by PE, a correlation between maternal blood 
pressure, proteinuria and placental vascular resistence was sought. One hundred 
and eighty pre-eclamptic patients were included in the study. They found that the 
uterine artery velocimetry was not related to the maternal blood pressure or the 
degree of proteinuria. However, abnormal arterial blood velocity waveforms on both 
sides of the placenta were significantly related to increased caesarean section rates, 
younger gestation at delivery, lower birth weight and increased frequency of 
admissions to the neonatal intensive care unit (NICU). Bilateral rather than unilateral 
uterine artery notches were predictive of poor perinatal outcome. This study 
concluded that the best predictor of adverse outcomes was a combination of 
umbilical and uterine artery Doppler waveform results. They could also be used to 
predict the need for operative interventions during labour and delivery (89).  
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To support the value of performing both uterine and umbilical artery Dopplers, a 
retrospective study looked at the frequency of increased uterine artery vascular 
impedence in the third trimester, its relationship to abnormal umbilical artery 
Doppler and adverse pregnancy outcomes. Five hundred and seventy pregnancies 
complicated by PE were analysed. Increased umbilical artery vascular impedence 
was seen in 59 cases (10.4%) whereas increased uterine artery pulsatility index or 
notching, or both were seen in 207 patients (36.3%). Signs of increased 
uteroplacental vascular impedence were more common in severe than in mild PE 
(57.4% vs. 31.4%). This study showed that only one-third of pre-eclamptic cases 
analysed showed signs of increased uterine artery vascular impedence in the third 
trimester. Increased vascular resistance was more frequent in the uterine than in the 
umbilical artery and was strongly related to adverse outcomes of pregnancy (90). 
Uterine artery Dopplers are technically difficult to perform in the third trimester and 
are discomforting for the patient especially when the presenting head has engaged 
into the pelvis. 
The use of uterine artery Doppler waveform in the third trimester in growth 
restricted infants delivered at ≥ 34 weeks gestation was looked at. This study was 
conducted over four years and all consecutive euploid singleton fetuses with 
accurate dating diagnosed with IUGR were included into the study. After PE was 
controlled for, it was found that in growth restricted infants delivered at ≥ thirty four 
weeks gestation, the presence of abnormal Doppler waveforms at the uterine 
arteries at diagnosis is associated with a four-fold increased risk of adverse neonatal 
outcomes (these events included increased rates of admission to NICU and low birth 
weights) (91).  
However, another study found that an abnormal umbilical artery waveform was a 
strong and independent predictor of adverse perinatal outcomes in patients with PE 
(92). This study looked at seventy two consecutive patients admitted with severe PE. 
Doppler velocimetry was performed within seven days of delivery and perinatal 
outcomes noted. Adverse perinatal included necrotising enterocolitis, APGAR score < 
seven at five minutes, perinatal death, acute renal failure and significant neonatal 
morbidity. After confounding variables were adjusted for, it was found that an 
abnormal umbilical artery waveform was a significant independant predictor of 
adverse perinatal outcomes (OR 14.2; p < 0.005) (92). Another study supporting the 
use of umbilical artery flow velocimetry alone included one hundred and seventy 
one women with hypertensive pregnancies at thirty six to forty two weeks gestation. 
The Doppler ultrasonography profile included umbilical artery Dopper flow 
velocimetry waveforms, amniotic fluid volume, fetal movements, placental grading 
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and fetal growth pattern. Doppler ultrasonography profiles were correlated with the 
neonatal outcome (one minute APGAR score or admission to the NICU as the main 
outcomes). Only four patients had PE. The majority of patients (one hundred and 
forty five) had gestational hypertension, while twenty two had chronic hypertension. 
Doppler ultrasonography was found to have a high predictive value in assessing fetal 
wellbeing in hypertensive pregnancies. They also concluded that the umbilical artery 
Doppler flow velocimetry alone is a significant variable in the multiple logistic 
regression analysis (93).  
 
CORRELATING CENTRAL HAEMODYNAMICS WITH UTEROPLACENTAL CIRCULATION 
A study using Doppler velocimetry measurements was designed to correlate the 
relationship between the uteroplacental circulation, central haemodynamics and 
perinatal outcomes in pregnancies complicated by severe PE. Patients enrolled into 
the study had no other medical conditions. Doppler investigations were performed 
on the maternal central haemodynamics as well as umbilical and uterine arteries on 
admission. Patients were divided into three groups based on their systemic vascular 
resistance levels. They were then followed up and perinatal outcomes analysed. An 
inverse relationship was noted between the left ventricular function and cardiac 
index, and vascular resistance. As the vascular resistance increased, the left 
ventricular and cardiac index decreased. Small for gestational age was found to be 
statistically significant in the group with high resistance and was postulated to be 
due to reduced blood flow to the uteroplacental circulation.  The authors concluded 
that in order to maintain adequate uteroplacental perfusion in pregnancies with high 
uterine artery resistance, a high cardiac output in low systemic-vascular-resistance 
might compensate (94).  
Two studies have shown a correlation between intra-uterine weight and maternal 
ventricular function. The first study was performed to compare the maternal cardiac 
function in patients with pregnancies complicated by intra-uterine growth restriction 
and those with small for gestational age babies. This study showed that in the intra-
uterine growth restriction group, maternal cardiac output was lower while the total 
vascular resistance was higher when compared to the mums in the small for 
gestational age group. A model using total vascular resistance, left atrial diameter, 
fetal middle cerebral artery pulsatility index and gestational age yielded a sensitivity 
of 96.2% and a specificity of 84.6% for the detection of intra-uterine growth 
restriction.The authors concluded that maternal echocardiography provides a 
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sensitive tool for identifying pregnancies complicated by intra-uterine growth 
restriction (95).  
 A second study showed that certain haemodynamic changes in pregnancies 
complicated by intra-uterine growth restriction preceded the clinical manifestation 
of the intra-uterine growth restriction. While physiologicial changes in blood 
pressure, heart rate and stroke output were seen in the small for gestational age 
group, in the IUGR group, the total vascular resistance (TVR) was increased.  A 
significant inverse linear correlation was observed between TVR and weight (r=0.83; 
p<0.001) (96). 
 
EFFECT OF TREATMENT 
Methyldopa is the most common antihypertensive drug used in pregnancy in our 
setting. A study looking at its effects on umbilical artery blood flow found that it 
decreases umbilical artery vascular resistance in mild PE and chronic hypertensive 
pregnant women. The study involved ninety patients who were subclassified as 
either treated or untreated chronic hypertensives, pre-eclamptics or normotensive 
patients. They were commenced onto treatment with methyldopa twenty four hours 
after admission. The pulsatility index was measured on two occasions i.e. day zero 
and day seven. This study showed a statistically significant decrease in the BP 
recordings in the chronic hypertensive patients only (p <0.05). The PI in the umbilical 
artery decreased in the treated pre-eclamptic and chronic hypertensive group, while 
there was no difference in the normotensive and untreated pre-eclamptics and 
chronic hypertensives. After treatment, there was no difference in the umbilical 
artery PI in all five groups and birth weights were similar (97).  
There has been contradicting results from studies looking at the effects of plasma 
volume expansion and drugs on Doppler velocimetry (98, 99, 100). For example, 
plasma volume expansion was not shown to influence the pulsatility indices of the 
umbilical and middle cerebral arteries in a study involving two hundred and sixteen 
patients with severe pre-eclampsia and other hypertension related complications. 
Patients were infused with 250mL hydroxyethyl starch 6% twice daily in 4 hours and 
NaCl 0.9% between these doses and with intravenous medication while the control 
group did not receive any plasma expanders. Measurements of the umbilical and 
middle cerebral pulsatility indices were done on 4 occasions and not found to be any 
different between the groups. The only difference was a significant decrease in the 
haemoglobin concentration as would be expected in the treatment group (98). A 
randomised trial of plasma volume expansion in hypertensive disorders of pregnancy 
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looked at the changes on the pulsatility indices of the fetal umbilical artery and 
middle cerebral artery after treatment was initiated. It was found that there was a 
significant decrease in the umbilical artery pulsatility index after both plasma volume 
expansion and dihydrallazine administration (99). The response to acute versus 
chronic antihypertensive drugs has also been evaluated. In patients with pregnancy-
induced hypertension, acute and chronic blood pressure reduction did not change 
the systolic / diastolic ratios in the umbilical or maternal brachial artery. This study 
did however show a transient rise in the uteroplacental systolic/diastolic ratio (100).  
Another study looked at the effect of a single oral dose of nifedipine compared to 
that of an infusion of hydralazine on central haemodynamics in pregnancies 
complicated by severe pre-eclampsia. There was a similar reduction in blood 
pressure and systemic vascular resistance and a similar rise in heart rate and cardiac 
output. There was a greater decrease in pulmonary capillary wedge pressures with 
dihydralazine (101). Magnesium sulphate and qingxintong administration have been 
found to increase the time average velocity and volume of blood flow (p<0.05) 
through the uterine and umbilical arteries in patients with pregnancy induced 
hypertension. This study compared thirty one patients with PIH and seventy one 
normotensive patients. Initially the TAV and Q values were low (p<0.05) but 
subsequently improved after treatment. Interestingly, this study also showed 
elevated levels of serum estriol and human placental lactogen levels (102). As 
discussed earlier, colour flow Doppler imaging is clearly a valuable predictive index of 
fetal and placental function (88). Another study mentioned above looked at the role 
of low dose aspirin (60mg) in the prevention of pre-eclampsia in a low risk 
population. Healthy nulliparous patients with a singleton pregnancy were enrolled 
into the study at twenty four weeks gestation. They were followed up throughout 
pregnancy with regular Doppler examinations of the umbilical arteries and adverse 
pregnancy outcomes noted. Logistic Regression model was used and treatment with 
aspirin was not found to affect the relation between Doppler indices and adverse 
pregnancy outcomes (80). 
 
ADVERSE MATERNAL AND FETAL OUTCOMES IN PRE-ECLAMPSIA 
In the mother, PE can manifest either as a mild syndrome with proteinuria and 
hypertension late in pregnancy or a severe disease with widespread endothelial 
dysfunction and end organ damage. It is a multisystem condition. Endothelial 
dysfunction is believed to be due to an imbalance in circulating vasoactive 
substances. This results in ‘leaky’ capillary beds which produces clinical edema. This 
may be generalised and patients are prone to pulmonary oedema. When cerebral 
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oedema is present, patients present with headaches, visual changes (e.g. blurrying of 
vision) and seizures. The hallmark renal lesion of PE is termed glomerular 
endotheliosis. It is associated with reductions in glomerular filtration rate (GFR) and 
proteinuria. Thrombotic microangiopathy, also known as The HELLP syndrome is 
characterised by Haemolysis, Elevated Liver enzymes and Low Platelets and develops 
in 10–20% of pregnancies complicated by severe PE (103). 
Women who previously experienced PE remain at increased long-term risk for 
cardiovascular and cerebrovascular events, relative to women with normotensive 
pregnancies (104). In a retrospective study of more than 1 million Canadian women, 
those who previously suffered PE, gestational hypertension, placental abruption, or 
placental infarction were twice as likely to develop premature cardiovascular disease 
at a median follow-up of 8.7 years, compared with those without a maternal 
placental syndrome (105). 
Furthermore infants of affected mothers are at risk for the complications of 
premature delivery, intrauterine growth restriction, oligohydramnios and still births 
(106).  
 
RATIONALE FOR THIS STUDY 
Non-invasive methods for cardiac monitoring have limitations; therefore there is a 
need for reliable biomarkers of cardiac function and risk assessment.  However the 
available biomarkers to date have not consistently been able to to discriminate 
among the different clinical phenotypes in hypertensive disorders of pregnancy. 
Hence there is a need for exploration of other biomarkers of PE. Given that the 
vasoconstriction and volume retention that characterises hypertensive disorders of 
pregnancy, it is possible that the biomarkers of cardiac stress may be useful in 
diagnosing women with these disorders. BNP is a protein released by the ventricles 
in the presence of myocytic stretch, and has been correlated to left ventricular filling 
pressures and, independently, to other cardiac morphological abnormalities. In 
addition, BNP is significantly affected by age, sex, renal function and obesity. Given 
its correlation with multiple cardiac variables, BNP has high sensitivity, but low 
specificity, for the detection of elevated left ventricular filling pressures. The clinical 
use of BNP to diagnose patients with heart failure is now well established but little is 
known about the clinical use of this marker in hypertensive disorders of pregnancy. 
There is evidence that cardiac function is altered in PE. Significant changes in the 
volume status and systemic resistance have been documented in patients with PE.  
Given that BNP is a protein released from the cardiac ventricles in response to 
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myocytic stretch, elevated left ventricular diastolic pressures cause elevation of 
plasma BNP. We performed Doppler studies of the heart and measured plasma BNP 
levels in pre-eclamptic and normotensive patients and correlate these findings with 
perinatal outcomes.  




STUDY DESIGN AND METHODS  
  
2.1. AIM AND OBJECTIVES  
AIM: 
The aim of this study is to identify haemodynamic changes in patients with pre-
eclampsia by evaluating serum BNP levels and performing Doppler studies of the 
heart and umbilical cord.  
OBJECTIVES: 
1) To evaluate the changes in volume status in PE using BNP and 
echocardiographic changes 
2) To evaluate the role of BNP in the management of PE 
3) To relate changes in BNP to fetal outcome as assessed by the APGAR score 
and fetal condition. 
 
2.2 STUDY DESIGN          
 Study population: 
      Consenting primigravidae in the third trimester of pregnancy 
 Sampling strategy:  
 Convenient sampling  
 Statistical planning (variables/ confounders): 
52 pre-eclamptic and 63 normotensive pregnant patients 
 Sample size: 
       115 patients  
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2.3. INCLUSION AND EXCLUSION CRITERIA 
 Inclusion criteria:   
1) Women in their first pregnancy who had a blood pressure of at least 
140mmHg systolic and 90 mmHg diastolic pressure on 2 occasions for the 
first time after the twentieth week of pregnancy. All women satisfying 
this criteria, had to have at least one plus of proteinuria on urinary 
dipstick. 
2) Patients in whom informed consent can be obtainable 
 Exclusion criteria:  
1) Multiple pregnancy 
2) Multigravidae 
3) History or clinical evidence of pre-existing hypertension/ cardiac or renal 
disease        
 
2.4. METHODOLOGY 
2.4.1 Data Collection Methods And Tools 
Selection of suitable participants was undertaken after discussion and obtaining 
informed consent (see appendix 1) from antenatal patients attending Prince 
Mshiyeni Memorial Hospital antenatal clinic in Durban. A full history and clinical 
examination was performed. Baseline blood investigations included a full blood 
count, urea and creatinine, urates and BNP levels. Proteinuria was tested for by the 
dipstick method (Ames). Echocardiography (including a Tissue Doppler Imaging) was 
performed by an experienced sonographer at recruitment. An obstetric ultrasound 
was performed on all patients. Fetal wellbeing was assessed at ultrasound in terms 
of appropriate growth for gestation and placental sufficiency with the aid of 
placental Doppler flow measurements. Pregnancies were followed and timing and 
mode of delivery noted. Plasma BNP levels were repeated during labour (or within 
24 hours post delivery). The baby at birth was assessed in respect of APGAR scores, 
admission to neonatal intensive care and condition on Day 7 following delivery. 
Maternal serum BNP was collected within the puerperium. 
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2.4.2. Data Analysis Techniques 
a) Echocardiography and Tissue Doppler 
All patients had standard M-mode 2-dimensional Doppler echocardiograms 
performed by the same highly skilled examiner who was unaware of the patient’s 
blood pressure values. Doppler echocardiography was performed using a HD imaging 
system (Philips) with phased array transducer and an emission frequency of 3.0 
megaHertz with the patient in the left decubitus position. Parameters were 
measured  e.g. the LV end-systolic and end-diastolic dimensions, LV wall thickness, 
and left atrial (LA) dimensions were measured according to American Society of 
Echocardiography guidelines using the leading edge method (107). The left atrial 
volume was estimated using the biplane ellipsoid formula. The LV end-systolic and 
end-diastolic volumes and the ejection fraction were measured from the apical four-
chamber view using the Modified Simpson’s method (108). Tissue Doppler Imaging 
(TDI) was performed with transducer frequencies of 1.8–3.6 MHz with minimum 
optimal gain as possible to obtain the best signal to noise ratio. The mitral inflow 
pattern was used to measure the peak early (E) and late (A) filling velocities End 
expiratory tissue Doppler views were obtained of the inferoseptal side of the mitral 
valve in pulsed mode. The angle between the Doppler beam and the longitudinal 
motion of the annulus was kept o a minimum in order to obtain the highest tissue 
velocities with the spectral pulse wave Doppler velocity adjusted to an approporiate 
range. The diastolic tissue velocity pattern at the annulus as used to measure the 
peak early (Ea) and late (Aa) tissue velocities. The ratio of the peak early mitral 
inflow velocity to the peak early tissue velocity (E/Ea) was calculated as an estimate 
of the left ventricular filling pressure. The following figures are shown of 2 randomly 
selected study patients. 
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Figure 1a: M-Mode recording in a normotensive patient (A) and in a pre-eclamptic 
patient (B).  
  
Patient A (Normotensive)    Patient B (Pre-eclamptic) 
 
Figure 1b: Doppler recordings in a normotensive patient (A) and in a pre-eclamptic 
patient (B) across the mitral valve.  
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Figure 1c: Tissue Doppler recordings in a normotensive patient (A) and in a pre-
eclamptic patient (B) across the lateral wall of the mitral valve annulus.  
 
Patient A (Normotensive)    Patient B (Pre-eclamptic) 
 
b) Brain Natriuretic Peptide 
Three venous blood samples were taken in plastic specimen tubes containing 
ethylenediaminetetraacetic acid (EDTA). Three specimens were collected from 
participants i.e. at the time of recruitment, intra-partum and the last specimen was 
collected from day 7 post delivery until the end of the peuperium. The samples were 
transported on ice to the laboratory where they were centrifugued. Standard 
handling of specimens was practised (109). The plasma was stored at −20°C and NT-
proBNP was assayed in batches by standard electrochemiluminescence 
immunoassay (“ECLIA”) using the Modular Analytics E170 (ELECYS module) and 
Elecsys 1010/2010 analyzer (Roche diagnostics,). Samples from cases and controls 
were stored for the same duration and were handled together, identically. According 
to the National Committee for Clinical Laboratory Standards (NCCLS) (109), the 
resting BNP values considered normal for this methodology lie below 100 pg/mL. The 
within-assay and total precision coefficients of variation for NT- proBNP mean 208 
pmol/l is 0.8% and 4.5% respectively. The reading sensitivity is <2.0-5000pg/ml (0.58-
1445pmol/L) 
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c) Fetal Ultrasound and Umbilical Artery Doppler 
Routine biometrical ultrasound was performed on patients using a Toshiba (Nemio) 
scanner in B-Mode. In B-Mode, the image shows all the tissue that is transversed by 
the ultrasound probe in a 2-dimensisonal view. It is also known as B-Mode sections. 
If multiple B-Mode images are watched in rapid sequence, they become ‘real time’ 
images (110). A low frequency (3.75 MegaHertz) curvilinear probe was utilised with 
patients lying supine. The sonographer was blinded to the study. Standard principles 
of measurements were used (111). The estimated fetal weight (EFW) was 
automatically calculated after measurement of the abdominal circumference (AC), 
femur length (FL) and biparietal diameter (BPD). BPD was measured as the distance 
between the parietal eminences on either side of the skull. The projection of the 
femur in a transverse section was identified. It was scanned at 90 degrees to contain 
a longitudinal section. Measurement was made from one end to the other end. The 
abdominal circumference was measured in a cross sectional view (as round as 
possible), at the level of the fetal liver. Antero-posterior and transverse diameter 
from the outer edge of the fetal abdomen on one side to the outer edge on the 
other side were used. The abdominal circumference was measured by multiplying 
the sum of the two dimensions by 1.57 i.e. AC= (AP diameter + T diameter)/1.57. 
Umbilical artery Doppler studies were then performed on all patients at the time of 
the fetal ultrasound. Pulsed wave Doppler was used to measure the speed of flow in 
the umbilical artery. The Resistance Index (RI) was computed by measuring the peak 
of systole and then dividing it by the sum of measurements at peak systole and 
diastole. RI= systole/ (systole+diastole)l as an average over three cardiac cycles 
(111). 
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Figure 2: Transabdominal ultrasound showing (a) normal umbilical artery Doppler in 
a normotensive pregnant patient and (b) absent end diastolic flow in the umbilical 
artery Doppler in a pre-eclamptic pregnant patient. 
 
Patient A         Patient B 
 
2.4.3. Statistical Analysis 
SPSS version 11.5 (SPSS Inc. Chicago ILL, USA) was used for statistical analysis. 
Outcome measures were BNP levels, echocardiographic findings and pregnancy 
outcomes in both groups. Chi square statistics or Fisher’s exact tests were used 
where appropriate to examine associations between categorical exposures and 
outcomes. Independent two sample t-tests were used to compare mean BNP levels 
between two categories. A p value of <0.05 was considered as statistically significant. 
Results are presented as variables and standard deviation (SD), and for BNP and U/S 
as median values with ranges in brackets. BNP values were not normally distributed 
and were log transformed for analysis. Spearmans test was used for correlation 
studies between BNP, TDI and RI. 
 
2.4.4. Funding 
Funding was obtained from The Department of Cardiology Research fund. 
 
2.4.5. Ethical Approval 
The University of KwaZulu/ Natal Postgraduate committee approved the study (PG 
032/08). Ethics approval was obtained from The University of Kwa Zulu-Natal 
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Biomedical Research Ethics Committee (Reference number: E335/05). Informed 
consent was obtained from all patients involved before inclusion into the study 
(Appendix 1). KwaZulu/Natal Department of Health approval was obtained in August 
2009. 






3.1 DEMOGRAPHIC DATA  
One hundred and fifteen primiparous pregnant patients gave consent to participate 
in the study. Fifty two patients were pre-eclamptic with a mean age of 21.5 ± 4.7 
years and sixty three patients were normotensive pregnancies with a mean age of 
20. 4 ± 3.7 years (p=0.063). The systolic and diastolic blood pressure of the pre-
eclamptic patients were significantly higher when compared to the normotensive 
pregnancies (p<0.001). There was no difference in gestational age at entry and in 
mode of delivery in both groups. Demographic data of the normotensive 
pregnancies and the pre-eclamptic patients are shown in Table 2. By design there 
were no differences in gestational age at enrolment. Gestational age at delivery was 
similar in both groups.  
 
HIV STATUS 
Seventeen patients in both groups were HIV positive of which five had CD4 cells 
count less than 200 cells/mm. 
 
BODY MASS INDEX (BMI) 
Both groups were considered overweight. There was no statistical significance in the 
body mass index between the pre-eclamptic group when compared to the 
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BMI (weight / height2 ) 
Gestational age at entry (wks) 
*Gestational age at delivery (wks) 
Edema 
HIV Infected 
Blood Pressure (mmHg) 
                SBP 
                DBP 
 Pulse (bpm)    
20.4 ± 3.7 
27.9± 5.5 
34.5 ± 2.7 




127.03 ± 12.9 
78.32 ± 8.6 
84.7 (72 - 96) 
21.5 ± 4.7 
29.4± 7.9 
34.3 ± 2.7 




163.2 ± 17.6 












SBP= systolic blood pressure; DBP= diastolic blood pressure; CVS=cardiovascular; 
bpm= beats per minute; SD= standard deviation 
*Gestational age at delivery for 7 normotensives and 1 pre-eclamptic could not be 
determined as they did not return for follow-up (n=56 and 51 respectively). 
 
3.2. LABORATORY INVESTIGATIONS 
The detailed laboratory analysis of serum and urine is shown in Table 3. There was 
no difference in hemoglobin levels between the two groups. Platelet count and 
haematocrit were lower in the pre-eclamptic group. Ten patients in the pre-
eclamptic group developed thrombocytopenia and one in the normotensive 
pregnancies. Serum urea, creatinine and uric acid levels were significantly elevated 
in the pre-eclamptic group. The mean level of proteinuria as assessed by dipstick was 
2+ in the pre-eclamptic group and 0 in the normotensive pregnancies.  
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Full blood count 
   Hemoglobin (g/dl) 
   Platelets (x109/L) 
   Haematocrit (%) 
Blood chemistry 
  Urea (mmol/L) 
  Creatinine (µmol/L) 
  Uric acid (mmol/L) 
Urine Dipstick 
   Proteinuria 
 
10.9 ± 1.3 
251.8 ± 82.8 
33.1 ± 3.1 
 
2.5 ± 0. 7 
54.5 ± 8.9 
0.27 ± 0.06 
 
0 (0 to 1+) 
 
11.3 ± 1.4 
215.5  ± 82.6 
34.2 ± 3.6 
 
3.08 ± 1.18 
62.4 ± 12.7 
0.33 ± 0.07 
 












3.3. FETAL ULTRASOUND AT INITIAL ASSESSMENT 
There was no difference in the GA and EFW between the groups. The liquor volume 
was adequate in 60 patients with the normotensive pregnancies and forty two in the 
pre-eclamptic group. In the normotensive group there was one patient with 
polyhydraminos and in one patient, the liquor volume was decreased. In the pre-
eclamptic group there were six patients with polyhydraminos and in three patients 
the liquor volume was decreased. The RI was significantly higher in the pre-eclamptic 
group compared to the normotensive group (0.68 ± 0.06 vs 0.63 ± 0.05; p<0.001). 
Results expressed as mean (+/-SD). Details are shown in Table 4.  








Gestational age (weeks) 






















Liquor volume Adequate (n=60) Adequate (n=42) 
 
3.4. ECHOCARDIOGRAPHY FINDINGS 
All the parameters between the two groups were within normal limits. There were 
no differences in chamber dimensions between the groups. The relevant data are 
shown in Table 5. 









LV Diastole (mm) 
LV Systole (mm) 
Fractionalshortening (%) 
Ejection fraction (%) 
LV posterior wall (mm) 
Septal thickness (mm) 
Left atrium (mm) 






































LV= Left Ventricular 
Ejection Fraction 
There was no difference in ejection fraction between the two groups. The details are 
shown in Table 5. 
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Tissue Doppler Imaging  
There were no significant differences in the tissue Doppler S wave or the Tissue 
Doppler E/Ea ratio in the pre-eclamptic group when compared to the normotensive 
pregnancies (11.02 ± 5.6 vs 9.16 ± 2.6; p=0.058).  
 
3.5. B-TYPE NATRIURETIC PEPTIDE LEVELS 
BNP type natriuretic levels were significantly increased in the antepartum (23.8 (2 - 
184.1) vs 6.0 (0.5 - 45.2) pmol/L; p<0.001), during labour (15.0 (1.8-206.4) vs 8.7 (1.9 
- 24.8) pmol/L; p=0.017) in the pre-eclamptic group compared to the normotensive 
pregnancies. BNP levels decreased in the postpartum period 4.2 (1.7-51.4) vs 5.95 
(2.2-38.7) pmol/L; p=0.140 in the pre-eclamptic and normotensive groups 
respectively to levels that were not significantly different.  Median values in both 
groups are shown below (Table 6, Fig 3) 
Table 6: BNP levels (median values plus range) in normotensive and pre-eclamptic 
pregnancies.  
Parameter N Normotensive N Pre-eclamptic p Value 
BNP  (p/mol) 
      Antepartum (1) 
      Labour (2) 






6.0 (0.5 - 45.2) 
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Figure 3: Median BNP at different timepoints in pregnancy 
 
Median BNP by PE and time point (Key: 1= antenatal, 2= intrapartum, 3= 
postpartum) 
 
3.6. CORRELATION STUDIES (TABLE 7) 
BNP1 and E/Ea and RI 
There was a small correlation between baseline BNP and E/Ea (r=0.22; p=0.051) at 
study enrolment. This was however not statistically significant. Statistical significance 
was found when BNP1 and umbilical artery Doppler RI at study enrolment were 
compared (r=0.321; p=0.001). It is important to note that the correlation was small 
and significant, possibly influenced by the sample size. 
 
BNP3 and E/Ea and RI 
There was no correlation between BNP after delivery and the predelivery E/Ea and RI 
parameters. 
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Table 7: Correlation of BNP, E/Ea and RI in the pre-eclamptic group 




Correlation Coefficient 1.000 .180 .222 -.293 
Sig. (2-tailed) . .110 .051 .060 
N 80 80 78 42 
RI 
Correlation Coefficient .180 1.000 .321** -.143 
Sig. (2-tailed) .110 . .001 .326 
N 80 113 106 49 
** Correlation is significant at the 0.01 level (2-tailed). BNP values were 
logarithmically transformed to get an appropriately distributed normal distribution. 
 
3.6. PREGNANCY OUTCOMES 
3.6.1. Maternal 
The number of maternal complications was higher in the pre-eclamptic group 
compared to the normotensive group. Details of the complications are shown in 
Table 8. 


















Thrombocytopenia = < 150 x109/L 
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ANTIHYPERTENSIVES TREATMENT USED IN THE PRE-ECLAMPTIC GROUP 
Thirty three pre-eclamptics required rapid acting antihypertensive for blood pressure 
control. The antihypertesive of the three patients are shown in Table 9. 
Echocardiography and BNP at enrolment were performed prior to the administration 
of antihypertensive therapy. 
Table 9 Antihypertensive regimen of pre-eclamptics (n=51) 
Antihypetensive regimen No 
Aldomet 
Adalat 
Adalat + MgSO4 
Adalat + Amlodipine 
Adalat + Hydrallazine 
Adalat + Hydrallazine +MgSO4 
Adalat+ Labetalol  










EMERGENCY POST DELIVERY CARE 
Seven pre eclamptics required emergency care after delivery; two were admitted to 
intensive care unit and five to high care. There were no normotensive patients 
admitted to high care or the intensive care unit. 
 
3.6.2 Mode Of Delivery  
The mode of delivery of 8 patients (7 patients in the normotensive group and 1 in 
the pre-eclamptic) could not be established as they did not return for follow up. The 
caesarean section rate was 47% in the pre-eclamptic group and 32% in the 
normotensive group (Fig 4). Because eight subjects were lost to follow-up, no 
inference could be made from this data. The mode of delivery and indication for 
cesarean section is shown in Table 10.  
 
 




Figure 4:  Flow diagram showing mode of delivery 
                                       Primigravidae (n=115) 
 
 
                                             Pre-eclamptics (n=52)                         Normotensives (n=63) 
                                
Mode of delivery          C/S         NVD        UNK                             C/S         NVD      UNK 
                                        (n=24)    (n=27)     (n=1)                        (n=18)     (n=38)     (n=7) 
 
 UNK = unknown 
Table 10: Indications for Caesarean section 
INDICATION FOR C/S PE (n=51) Normotensive (n=56) 
Severe PE 7 0 
Eclampsia 4 0 
Fetal distress 6 5 
CPD 0 3 
Big baby 0 2 
Failed IOL 2 1 
Poor progress 1 3 
Breech presentation 1 1 
PROM 1 2 
MSL 3 0 1 
An/oligohydramnious 2 0 
Page | 48  
 
 
3.6.3. Perinatal Outcome 
There was no difference in the number of live births between the 2 groups. The 
birthweight was significantly lower in the pre-eclamptic pregnancies compared to 
the normotensives (2.6 ± 0.8 kg vs 3.14± 0.42 kg; p<0.0001). One neonate in the pre-
eclamptic group was born with Down’s syndrome. 
Table 11: Perinatal outcome in the pre-eclamptic and normotensive pregnancies. 




Birth weight (kg) 
Apgar scores 
           I min 
           5 min 








Perinatal outcome PE (51) Normotensive (56) 
Live births 47 55 
Still births 2 0 
ENND 1 1 
 
Early Neonatal Deaths 
1) Patient 1, a 25yr old P0G1, HIV infected patient, presented at 28 weeks of 
gestation with blood pressure of 224/134 mmHg, pulse 106 beats per minute, 
proteinuria 2+, edema 1+. Tissue Doppler E/Ea was markedly elevated at 42, as 
was the RI (0.74), uric acid levels (0.43) and she had a thrombocytopenia (122 x 
109/L). She was in pulmonary edema. She was given rapid acting blood pressure 
lowering drugs (nifedipine, hydrallazine, labetalol, methyldopa and MgSO4) and 
intravenous diuretics. She had an induction of labor at 30 weeks and delivered 
1kg baby with poor Apgar scores who died an hour later.  
2) Patient 2, a 24 year old P0G1 HIV negative patient, presented at 40 weeks of 
gestation with BP of 126/82 mmHg. Tissue Doppler E/Ea was 15.4, RI 0.67, 
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ejection fraction 68%. She delivered a 3.4 kg baby with low APGAR scores that 
died two days later from acute respiratory distress. 
 
Stillbirths  
1) A 23 yr old booked patient presented with severe lower abdominal pain and 
decreased fetal movements. She was receiving highly active antiretroviral 
therapy with a CD3 count of 173 cells/ uL. She was pre-eclamptic with baseline 
BP 154/94 and 1+ proteinuria. She was diagnosed with an abruptio placentae 
Grade 3B. She delivered a 3.0 kg macerated stillborn. Tissue Doppler E/Ea was 
13.24 and BNP 20.8pmol/L. Post-delivery the BNP fell to 2.7pmol/L. 
2)  29 year old patient presented with imminent eclampsia. She was HIV infected 
with a CD4 count of 200 cells/uL. Her BP was 175/ 110. Ultrasound confirmed the 
diagnosis of an intra-uterine death and no visible pools of liquor (she gave no 











Pre-eclampsia is associated with vasoconstriction and increased left ventricular 
afterload accompanied by a reduced cardiac output, hypovolemia and low to normal 
or slightly increased cardiac filling pressures (112). This study shows that the 
haemodynamic changes that accompany PE are associated with significant changes 
in LV filling as reflected by increased BNP levels. 
Hypertensive disorders of pregnancy contributed to 15.7% of maternal deaths in 
South Africa. According to the NCCEMD 2005-2007 report, this is second only to 
AIDS-related deaths. Of note is that 53% of these deaths were clearly avoidable. It is 
vital that all health care providers are aware of the severity of this condition, the 
availability of markers, and the correct treatment of this common obstetric 
condition. It is important to study primigravidae, as so called “true PE” usually occurs 
in first pregnancies after the the 34th week of pregnancy. Thus, our patients could 
be considered a homogenous group of patients. Furthermore, all our patients were 
Black South Africans who were Zulu speaking. Most other studies included 
heterogenous population groups (113, 114). 
In women with PE, there may be modification of left ventricular structure and 
function due to the increase in systemic blood pressure. Furthermore, there is a 
statistically significant increase in left ventricular mass. Increased left ventricular 
end-systolic and end-diastolic volumes have also been demonstated while significant 
reductions in left ventricular ejection fraction and percentage of fractional 
shortening have been found (112). The ejection fraction between the two groups 
was insignificant in our study possibly due to the fact that even in heart failure, up to 
40-50% of patients may still have normal ejection fractions (115). 
An increasingly popular marker of increased left ventricular filling pressure is 
assessment by tissue Doppler imaging. Our study showed no difference in the tissue 
Doppler E/Ea ratio between the pre-eclamptic and normotensive groups (11.02 ± 5.6 
vs 9.16 ± 2.6 p=0.058) or in any of the other measured parameters. 
BNP is a recognised marker of patients with LV dysfunction. In patients with PE, BNP 
has been observed to be linearly related to the left ventricular structural and 
functional changes seen (116) and even in non pregnant patients with a wide range 
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of hemodynamic changes, circulating levels of BNP were shown to be independently 
associated with cardiac sstress and risk of progressive heart failure and death (117). 
It has been established that BNP is synthesised by cardiac atrial and ventricular 
myocytes and released into blood in response to stretch. Evidence shows that NT-
proBNP measurement is superior to ANP in the detection of mild systolic heart 
failure, diastolic heart failure, and asymptomatic left ventricular dysfunction because 
of its longer half - life (41, 118. 119).  
Numerous studies have looked at the relationship between BNP and PE. In a recent 
study, Tihtonen et al. (2007) found that concentrations of natriuretic peptides (NT-
pro-BNP and NT-pro-ANP) were significantly higher in PE than in the normotensive` 
and those with chronic hypertension (120). Frantz et al, in 2009 and Kale et al, in 
2005 have confirmed that BNP concentrations are elevated in PE and other 
hypertensive disorders of pregnancy than in normal pregnancy (121, 122). 
Furthermore, the long term risk of death from cardiovascular disease is higher in 
women who have had pre-eclampsia (123). 
Women with PE have increased sensitivity to angiotensin II resulting in increased 
peripheral vasoconstriction and volume retention (124). BNP is associated with a 
derangement in the renin-angiotensin system. It suppresses renin release (125). BNP 
also suppresses endothelin release which is an additional mechanism to regulate 
vascular tone. Factors such as pro inflammatory cytokines and endothein-1 are also 
known to stimulate natriuretic peptide release. Furthermore, the intense 
vasoconstriction observed in PE, may lead to myocardial remodelling with subclinical 
ventricular dysfunction and activation of BNP (126). It is now known that circulating 
plasma BNP levels are increased even in healthy pregnancies but the increased 
serum BNP levels in PE are greater than in normotensive pregnancies (127). This 
suggests that BNP activation in PE is a response to the pathophysiological changes in 
the utero-placental circulation. 
We have shown that plasma BNP levels were significantly increased in the pre-
eclamptic compared to the normotensive patients in the antepartum period; and 
decreased in the post partum period.  While it appears that the increase in 
circulating plasma BNP is most likely explained by the rising cardiac filling pressure, it 
should be remembered that PE is documented to be a relatively hypovolaemic state 
with peripheral vasoconstriction. Our findings suggest that BNP may be involved in 
the pathophysiolgy of PE. This hypothesis is confirmed by the decrease in BNP levels 
in the puerperium when the placenta has been removed.  
Page | 52  
 
 
The correlation between elevated blood pressures and clinical indices were clearly 
demonstrated in this study. Significant changes were seen in the pre-eclamptic 
group with regard to blood pressure, pedal oedema, proteinuria, uric acid and serum 
creatinine levels, highlighting the need for intervention These are but a few of the 
well documented indicators of worsening disease progression of PE and the need for 
prompt intervention highlighted. The relationship between proteinuria and the heart 
need further evaluation as well as its relationship to HIV infection.  
Our study showed a statistically significant increase in the RI on umbilical Doppler 
velocimetry. Doppler velocimetry of the umbilical cord has been found to be a more 
specific and sensitive method of fetal surveillance than cardiotography. It is a fast 
and convenient method for monitoring fetal well being. Its importance in high risk 
pregnancies is well documented (128-131). A study looking at the perinatal 
outcomes in babies born to mums with severe PE showed that an abnormal Doppler 
umbilical artery waveform is a strong predictor of perinatal mortality and is 
associated with a poor perinatal outome. Of note is that neonates with abnormal 
pulsatility index had lower birth weights, lower APGAR score at 5 minutes, higher 
admission rates to the neonatal intensive care units and significant neonatal 
morbidity as compared to those with normal velocimetry (p<0.05) (83). The umbilical 
artery circulation is normally a low impedence circulation with an increase in the 
amount of end-diastolic flow with advancing gestation (132). Umbilical artery 
Doppler waveforms reflect the status of the placental circulation. With increasing 
gestation, there is an increase in the end-diastolic flow as a result of an increase in 
the number of tertiary stem villi that occurs with placental maturation (133, 134). 
Another study showed that a when the fetal growth velocity was reduced, changes 
in fetal circulation preceded this. Ratios of the fetal Doppler parameters provides 
clear evidence of deterioration in the fetal condition which can aid in the diagnosis 
and management of the intra-uterine growth-restricted fetus (135) 
In our study, 7 pre-eclamptic patients required emergency care post delivery in 
keeping with the association between PE and adverse pregnancy events. An 
increased rate of caesarean sections, lower APGAR scores, lower birthweight and an 
increased admission rate to NICU has been described in PE (136, 137). Our study 
showed an increase in the number of abdominal deliveries in the pre-eclamptic 
group when compared to the normotensive control group. The caesarean section 
rate was 47% in the pre-eclamptic group and 32% in the normotensive group. Eight 
subjects were lost to follow-up, therefore no inference could be made from this 
data. The two highest indications were fetal distress (n=6) and hypertensivers 
disorders of pregnancy namely PE and eclampsia (n=11) in the PE group. In the 
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normotensive control group, the greatest indications for caesarean sections were 
fetal distress (n=5) followed by cephalopelvic disproportion (CPD) (n=5). The lower 
birthweight in the pre-eclamptic group is most likely due to placental insufficiency. 
Of the 7 pre-eclamptics who required emergency care, 2 required ICU admission. 




CONCLUSIONS, RECOMMENDATIONS AND LIMITATIONS 
 
5.1. CONCLUSION 
PE is a leading cause of maternal and fetal/neonatal mortality and morbidity (1). 
Therefore the early identification of patients with an increased risk for PE is 
important. The availability of highly sensitive and specific biochemical markers would 
allow not only for early detection of patients at risk but also permit close 
surveillance. This study showed that there are significant differences in BNP during 
PE and this reflects the haemodynamic changes in this condition. Serum BNP levels 
were significantly elevated in pregnancies complicated by PE, particularly in those 
with more severe disease. There was no statistical difference in the Tissue Doppler 
(E/Ea ratio) between the two groups. No inference could be made to the post 
delivery findings as eight patients were lost to follow-up.  
 
5.2. RECOMMENDATIONS 
BNP levels in asymptomatic pregnant patients were found to have little clinical value 
as they were not markedly elevated. However, there is clear evidence of its 
activation in PE and as in the non-pregnant patient; it could be used to identify left 
ventricular dysfunction. It could be particularly beneficial in symptomatic patients. 
Further research is needed to evaluate whether or not NT-pro-BNP can be used as an 




As mentioned, most of the changes in BNP occurred within normal ranges for our 
laboratory. The presence and extent of any structural changes may indeed be 
disease-specific, occurring in some conditions but not in others (138) and also likely 
that BNP activation is more pronounced in severe PE.  
In vitro stability of BNP and NT-proBNP after patient collection is also an important 
consideration, particularly when samples are referred to an outside laboratory for 
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testing. Reports indicate that BNP is stable in either EDTA whole blood or plasma for 
up to 24 hours if the specimen is refrigerated. Frozen plasma specimens for BNP 
measurement are reportedly stable for approximately 3 months. NT-proBNP is stable 
for up to 3 days when plasma or serum is stored refrigerated; NT-proBNP appears to 
be stable for years when frozen at −70° C. Overall, available data indicate that in 
vitro measurements of NT-proBNP are more stable compared to those of BNP. We 
addressed the stability issue by transporting all our specimens on ice. 
The study was conducted on patients in the 3rd trimester. Earlier recruitment might 
have shown whether or not BNP could be used as an earlier marker of PE. One of the 
difficulties in this study was that patient compliance and follow up was not ideal, due 
to numerous reasons, mainly socio-economic. Most subjects wished to be 
discharged immediately after delivery, making follow up evaluation difficult. 
Our study included 115 primigravidae with a mean age of 20 years in the 
normotensive and 22 years in the pre-eclamptic groups respectively. The mean BMI 
in the normotensive group was 27.852 while in the pre-eclamptic group it was 
29.342 (p=0.129). Extremes of age, nulliparity and an increased body mass index are 
well documented risk factors for pre-eclampsia. Obesity has been found to increase 
the risk of pre-eclampsia three-fold and this risk increases linearly with increasing 
body mass index. Besides increasing the rates of pre-eclampsia, escalating obesity 
also increases perinatal morbity (139). 
Lastly, repeating this study would call for substantial funding since BNP is an 
expensive laboratory investigation. Follow up studies may be limited. 
 
5.4. DISCLOSURE OF INTEREST 
No conflict of interest is disclosed by the author. 




1. De Swiet. Maternal mortality: confidential enquiries into maternal deaths in the 
United Kingdom.  Am J Obstet Gynaecol 2000; 182: 760-766. 
2. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric 
morbidity: case control study. Br Med J 2001 322: 1089-1093. 
3. Panday M, Mantel GD, Moodley, J. Audit of severe acute morbidity in hypertensive 
pregnancies in a developing country. J Obstet Gynaecol 2004; 24 (4): 387-91). 
4. Duley, L. Maternal mortality associated with hypertensive disorders of pregnancy 
in Africa, Asia, Latin America and the Caribbean (Confidential Enquiry in maternal 
mortality) BJOG 2009; 116: 247-256. 
5. National Committee for Confidential Enquiries into Maternal Deaths. Saving 
Mothers 2005-2007: Fourth Report on Confidential Enquiries into Maternal Deaths in 
South Africa. Pretoria: National Department of Health; 2008. 
6. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working 
Group on Research on Hypertension during Pregnancy. Hypertension. 2003; 41:437–
445. 
7. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799. 
8. Duley L, Meher S, Abalos E. Clinical review: Management of pre-eclampsia. BMJ 
Volume 332 February 2006. 463-488. 
9. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system 
in pre-eclampsia. Mol Aspects Med. 2007; 28:192–209. 
10. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal 
pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006; 13:680–
686. 
11. Catov JM, Ness RB, Kip KE, Olsen J. Risk of early or severe pre-eclampsia related 
to pre-existing conditions. Int J Epidemiol. 2007; 36:412–419. 
12. Podymow T, August P. Hypertension in pregnancy. Adv Chronic Kidney Dis 2007; 
14:178–190. 
13. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Pre-
eclampsia: A renal perspective. Kidney Int. 2005; 67:2101–2113. 
Page | 57  
 
 
14. Redman CW, Sargent IL. Latest advances in understanding pre-eclampsia. 
Science. 2005; 308:1592–1594. 
15. Huppertz B. Placental origins of pre-eclampsia: challenging the current 
hypothesis. Hypertension. 2008; 51:970–975. 
16. Roberts JM, Hubel CA. The two stage model of pre-eclampsia: variations on the 
theme. Placenta. 2009; 30:S32–S37. 
17. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxia-reoxygenation: a 
potent inducer of apoptotic changes in the human placenta and possible etiological 
factor in preeclampsia. Circ Res. 2002; 90:1274–1281. 
18. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and 
management of pre-eclampsia. JAMA. 2002; 287: 3183–3186. 
19. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Pre-
eclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161:1200–1204. 
20. Soleymanlou N, Jurisica I, Nevo O, et al. Molecular evidence of placental hypoxia 
in pre-eclampsia. J Clin Endocrinol Metab. 2005; 90: 4299–4308. 
21. Hansson SR, Chen Y, Brodszki J, et al. Gene expression profiling of human 
placentas from pre-eclamptic and normotensive pregnancies. Mol Hum Reprod. 
2006;12:169–179.  
22. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine 
kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and 
proteinuria in pre-eclampsia. J Clin Invest. 2003; 111: 649–658. 
23. Schutte JM, Schuitemaker NW, van RJ, Steegers EA. Substandard care in maternal 
mortality due to hypertensive disease in pregnancy in the Netherlands. Br Med 
Obstet Gynecol. 2008; 115:732–736.  
24. Von Dadelszen P, Magee LA, Roberts JM. Subclassification of pre-eclampsia. 
Hypertens Pregnancy. 2003; 22:143–148.  
25. Heikkila A, Tuomisto T, Hakkinen SK, Keski-Nisula L, Heinonen S, Yla-Herttuala S. 
Tumor suppressor and growth regulatory genes are overexpressed in severe early-
onset pre-eclampsia–an array study on case-specific human pre-eclamptic placental 
tissue. Acta Obstet Gynecol Scand. 2005; 84:679–689.  
Page | 58  
 
 
26. Tsui NB, Chim SS, Chiu RW, et al. Systematic micro-array based identification of 
placental mRNA in maternal plasma: towards non-invasive prenatal gene expression 
profiling. J Med Genet. 2004; 41:461–467. 
27. Ng EK, Leung TN, Tsui NB, et al. The concentration of circulating corticotropin-
releasing hormone mRNA in maternal plasma is increased in pre-eclampsia. Clin 
Chem. 2003; 49:727–731.  
28. Pang ZJ, Xing FQ. Comparative profiling of metabolism-related gene expression in 
pre-eclamptic and normal pregnancies. Arch Gynecol Obstet. 2004; 269:91–95.  
29. Gack S, Marme A, Marme F, et al. Pre-eclampsia: increased expression of soluble 
ADAM 12. J Mol Med. 2005; 83: 887–896.  
30. Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, Friese K. Microarray analysis 
of differentially expressed genes in placental tissue of pre-eclampsia: up-regulation 
of obesity-related genes. Mol Hum Reprod. 2002; 8: 674–680. . 
31. Enquobahrie DA, Meller M, Rice K, Psaty BM, Siscovick DS, Williams MA. 
Differential placental gene expression in pre-eclampsia. Am J Obstet Gynecol. 2008; 
199:1–11.  
32. Ng EK, Tsui NB, Lau TK, et al. mRNA of placental origin is readily detectable in 
maternal plasma. Proc Natl Acad Sci USA. 2003; 100:4748–4753.   
33. Tsui NB, Lo YM. A microarray approach for systematic identification of placental-
derived RNA markers in maternal plasma. Methods Mol Biol. 2008; 444:275–289.   
34. Zhou R, Zhu Q, Wang Y, Ren Y, Zhang L, Zhou Y. Genomewide oligonucleotide 
microarray analysis on placentae of pre-eclamptic pregnancies. Gynecol Obstet 
Invest. 2006; 62:108–114.  
35. Herse F, Dechend R, Harsem NK, et al. Dysregulation of the circulating and tissue-
based renin-angiotensin system in pre-eclampsia. Hypertension. 2007; 49:604–611. 
36. Heazell AE, Brown M, Dunn WB, et al. Analysis of the metabolic footprint and 
tissue metabolome of placental villous explants cultured at different oxygen tensions 
reveals novel redox biomarkers. Placenta. 2008; 29:691–698.  
37. Kenny LC, Broadhurst D, Brown M, et al. Detection and identification of novel 
metabolomic biomarkers in pre-eclampsia. Reprod Sci. 2008; 15:591–597.  
Page | 59  
 
 
38. Clerico A, Iervasi G, Mariani G. Clinical relevance of the measurement of cardiac 
natriuretic peptide hormones in humans. Horm Metab Res. 1999; 31:487–498.  
39. Maisel A. B-type natriuretic peptide levels: a potential novel “white count” for 
congestive heart failure. J Cardiac Failure. 2001; 7:183–193. 
40. Selvais P, Donckier J, Robert A, et al. Cardiac natriuretic peptides for diagnosis 
and risk stratification in heart failure: influences of left ventricular dysfunction and 
coronary artery disease on cardiac hormonal activation. Eur J Clin Invest. 1998; 
28:636–642.  
41. Yamamota K, Burnett J, Jougasaki M, et al. Superiority of brain natriuretic 
peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and 
ventricular hypertrophy. Hypertension. 1996; 28:988–994.  
42. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in 
assessment of patients with possible new heart failure in primary care. Lancet. 1997; 
350:1349–1353.  
43. Janssen WM, de Zeeuw D, van der Hem GK, de Jong PE. Antihypertensive effect 
of a 5-day infusion of atrial natriuretic factor in humans. Hypertension. 1989; 
13:640–646.  
44. Clerico A, Iervasi G, Del Chicca M, et al. Circulating levels of cardiac natriuretic 
peptides (ANP and BNP) measured by highly sensitive and specific 
immunoradiometric assays in normal subjects and in patients with different degrees 
of heart failure. J Endocrinol Invest. 1998; 21:170–179.  
45. Hawkridge AM, Heublein DM, Bergen HR, et al. Quantitative mass spectral 
evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe 
human heart failure. Proc Natl Acad Sci USA. 2005; 102:17442–17447. 
46. Boomama F, Van der Meiracker AH. Plasma A- and B-type natriuretic peptides: 
physiology, methodology and clinical use. Cardiovasc Res. 2001; 51:442–449.  
47. Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state 
(pregnancy) on left ventricular performance in normal human subjects. Circulation 
1978; 58: 434-414. 
 
48. Claudio Borghio, Daniela Degli Esposti, Vincenzo Immordino, et al. Relationship of 
systemic hemodynamics, left ventricular structure and function, and plasma 
Page | 60  
 
 
natriuretic peptide concentrations during pregnancy complicated by pre-eclampsia. 
Am J Obstet Gynecol 2000; 183: 140-147 
49. Desai DK, Moodley J, Naidoo DP. Echocardiology assessment of cardiovascular 
dynamics in normal pregnancy. Obstet Gynaecol 2004; 104: 20-26. 
50. Bamfo J, Kametas N, Chambers B, et al. Maternal cardiac function in 
normotensive and pre-eclamptic intra-uterine growth restriction. Ultras Obstet 
Gynaecol 2008; 32 (5): 682 – 686. 
51. Isaaz K, Thompson A, Ethevenot G, et al. Doppler echocardiographic 
measurement of low velocity motion of the left ventricular posterior wall. Am J 
Cardiol 1989; 64: 66-75. 
52. Gulati VK, Katz WE, Follansbee WP, et al. Mitral annular descent velocity by 
tissue Doppler echocardiography as an index of global left ventricular function. Am J 
Cardiol 1996; 77: 979-984. 
53. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler 
tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 
1997; 30: 474-480. 
54. Kati M, Kale E, Yalinkaya A, et al. Natriuretic peptides and haemodynamics in pre-
eclampsia. Am J Obstet Gynecol 2007; 18:328-330 
55. Speksnijder L, Rutten J, van den Meiracker A, et al. Amino-terminal pro-brain 
natriuretic peptide (NT-proBNP) is a biomarker of cardiac filling pressures in pre-
eclampsia.Eur J Obstet Gynecol 2010; 1-4. 
56. Bernard MY Cheung, Cyrus R. Kumana. Natriuretic peptides – relevance in 
cardiovascular disease. JAMA 1998; 280 (23):1983-84. 
57. Seino Y, Ogawa A. Yamashita T, et al. Application of NT-proBNP and BNP 
measurements in cardiac care: a more discerning marker for the detection and 
evaluation of heart failure. Eur J Heart Fail 2004; 6: 295-300. 
58. Steiner J, Guglin M. BNP or NT-proBNP? A clinician’s perspective. Int J Cardiol 
2008; 129: 5-14. 
59. Padubidri V, Anand E. Textbook of Obstetrics 2006; 20: 170-180  (BI Publications 
Pvt Ltd, 2006) ISBN, 817225223. 
Page | 61  
 
 
60. Furuhashi N, Kimura H, Nagae H, Yajima A, Kimura C, Saito T. Brain Natriuretic 
Peptide and atrial natriuretic peptide levels in normal pregnancy and pre-eclampsia. 
Gynecol Obstet Invest. 1994; 38 (2): 73-7. 
61. Resnik J, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) 
levels in normal and pre-eclamptic patients. Am J Obstet Gynecol 2005 193; 450-5. 
62. Itoh H, Sagawa N, Mori T, Mukoyama M, Nakao K, Imura H. Plasma brain 
natriuretic peptide level in pregnant women with pregnancy-induced hypertension. 
Obstet Gynecol. 1993; 82 (1):71-7. 
63. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in CHF 
what’s next? Circulation 2002; 105: 2328-31. 
64. Tihtonen KM, Kooobi T, Vuolteenano O, et al. Natriuretic peptides and 
haemodynamics in pre-eclampics.  Am J Obstet Gynecol. 2007; 196(4):328-335. 
65. Folk JJ, Lipari CWm Nosovitch JT, Silverman RK, Carlson RJ, Navone AJ. Evaluating 
ventricular function with B-type natriuretic peptide in obstetric patients. J Reprod 
Med. 2005 Mar;50(3):147-154. 
66. Okuno S, Hamada H, Yasuoka M, et al. Brain natriuretic peptide and cyclic 
guanosine monophosphate levels in normal pregnancy and pre-eclampsia – J Obstet 
Gynaecol Res. 1999 Dec;25(6):407-10. 
67. Bayes-Genis A, Lopez L, Zapico E, et al. NT pro-BNP reduction percentage during 
admission for acutely decompensated heart failure predicts long-term cardiovascular 
mortality. J Card Fail 2005; 11 (5):28-32. 
68. Kaaja R, Moore M, Yandle T,  Ylikorkala O, Frampton CM, Nicholis MGl. Blood 
pressure and vasoactive hormones in mild pre-eclampsia and normal pregnancy – 
Hypertens Pregnancy. 1999; 18(2):  173-187 . 
69. Abramowicz JS, Sheiner E. In utero imaging of the placenta: importance for 
diseases of pregnancy. Placenta. 2007 Apr; 28 Suppl A: S14-22.  
70. Harrington K, Goldfrad C, Carpenter RG,  Campbell S. Transvaginal uterine and 
umbilical artery Doppler examination of 12-16 weeks and the subsequent 
development of pre-eclampsia and intra-uterine growth restriction. Ultras Obstet 
Gynaecol 1997; 9(2): 94-100. 
71. Brodszki J, Lanne T, Laurini R, Strevens H, Wide-Swensson D, Marsal K. Vascular 
mechanical properties and endothelial function in pre-eclampsia with special 
Page | 62  
 
 
reference to bilateral uterine artery notch. Acta Obstet Gynaecol Scand 2008; 87(2): 
154-6. 
72. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery 
Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth 
retardation and perinatal death? An overview. BJOG. 2000; 107:196–208. 
73. Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler 
ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a 
systematic review and bivariable meta-analysis. CMAJ. 2008; 178:701–711.  
74. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH. Maternal 
endothelial function and serum concentrations of placental growth factor and 
soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol. 
2008; 32:871–876.  
 75. Todros T, Ferrazzi E, Arduini D, et al. Performance of Doppler ultrasonography as 
a screening test in low risk pregnancies: results of a multicentric study. J Ultrasound 
Med. 1995 May; 14(5): 343-8). 
76. Ivanov S, Mikhova M, Sigridov I, Batashki I. Doppler velocimetry in patients with 
pre-eclampsia. Akush Ginekol (Sofiia). 2006; 45(2):3-9 
77. Martin AM, Bindra R, Curcio P, et al. Screening for pre-eclampsia and fetal 
growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound 
Obstet Gynecol 2001;18:583-6. 
78. Albaiges G, Missfelder-Lobos H, Lees C, et al. One-stage screening for pregnancy 
complications by color Doppler assessment of the uterine arteries at 23 weeks' 
gestation. Obstet Gynecol 2000;96:559-64. 
79. Ekici E, Vicdan K, Davan H, Danisman N, Gokmen O. Reverse end-diastolic uterine 
artery velocity in a pregnant woman complicated by mild pre-eclampsia and severe 
growth retardation. Eur J Obstet Gynecol Reprod Biol. 1999 May; 66(1):79-82. 
80. Atkinson MW, Maher JE, Owen J, Hauth J Goldenberg RL, Cooper Rl. The 
predictive value of umbilical artery Doppler studies for Pre-eclampsia or fetal growth 
retardation in a pre-eclamptic prevention trial. Obstet Gynecol. 1994 Apr; 83(4):609-
12. 
81. Ruhle W, Ertan AK, Gnirs J, Schmidt W. Doppler ultrasound in obstetrics-
contribution to understanding reverse flow in the umbilical artery. Ultraschall Med. 
1991 Jun; 12 (3): 134-8. 
Page | 63  
 
 
82. Wang KG, Chen CP, Yang Jm, Su TH. Impact of reverse end-diastolic flow velocity 
in umbilical artery on pregnancy outcome after the 28th gestational week. Acta 
Obstet Gynecol Scand. 1998 May; 77(5):527-31. 
83. Arauz JF, Leon JC, Velasquez PR, Jimenez GA, Perez CJ. Umbilical artery Doppler 
velocimetry and adverse perinatal outcome in severe pre-eclampsia. Ginecol Obstet 
Mex. 2008 Aug;76(8):440-9. 
84. Sezik M, Tuncay G, Yapar EG. Prediction of adverse neonatal outcomes in pre-
eclampsia by absent or reversed end-diastolic flow velocity in the umbilical artery. 
Gynecol Obstet Invest. 2004; 57(2):109-113. 
85. Rocca MM, Said MS, Khamis MY, Ghanem IA, Karkour TA. The value of Doppler 
study of the umbilical artery in predicting perinatal outcome in pre-eclamptic 
patients. J Obstet Gynecol. 1995 Oct; 21(5): 427-431. 
86. Lacin S, Demir N, Koyuncu F, Goktay Y. Value of intraplacental villous artery 
Doppler measurements in Severe Pre-eclampsia. J Postgrad Med. 1996 Oct-Dec; 
42(4):101-4. 
87. Pirhonen J, Erkkola R. Flow velocity waveforms in the uterine artery in high risk 
pregnancies. Ann Chir Gynaecol Suppl. 1994; 208:98-9. 
88. Joern H, Rath W. Comparison of Doppler sonographic examinations of the 
umbilical and uterine arteries in high risk pregnancies. Fetal Diagn Ther. 1998 May-
Jun; 13(3):150-3. 
89. van Asselt K, Gudmundsson S, Lindqvist P, Marsal K. Uterine and umbilical artery 
velocimetry in Pre-eclampsia. Acta Obstet Gynecol Scand. 1998 Jul; 77(6):614-9. 
90. Li H, Gudnason H, Olofsson P, Dubiel M, Gudmungsson S. Increased uterine 
artery vasculature impedance is related to adverse outcome of pregnancy but is 
present in only one-third of late third-trimester pre-eclamptic women. Ultrasound 
Obstet Gynecol. 2005 May; 25(5):459-63.  
91. Vergani P, Roncaglia N, Andreotti C, et al. Prognostic value of uterine artery 
Doppler velocimetry in growth-restricted foetuses delivered near term. Am J Obstet 
Gynecol. 2002 Oct; 187(4):  932-6. 
 
Page | 64  
 
 
92. Yoon BH, Lee CM, Kim SW. An abnormal umbilical artery waveform: a strong and 
independent predictor of adverse perinatal outcome in patients with pre-eclampsia. 
Am J Obstet Gynecol. 1994 Sep; 171(3):713-21. 
93. Romero Gutierrez G, Aqilar Barajas I, Chavez Curiel A, Ponce Ponce de Leon AL. 
Prediction of fetal wellbeing with Doppler flow metric profile in pregnant 
hypertensive women. Ginecol Obstet Mex. 2001; 69: 480-6. 
94. Jang JM, Yang YC, Wang KG. Central and peripheral haemodynamics in severe 
pre-eclampsia. Acta Obstet Gynecol Scand. 1996 Feb; 75(2):120-6. 
95. Bamfo JEAK, Kametas NA, Chambers JB, Nicolaides KH. Maternal cardiac function 
in growth restricted and non growth restricted small-for-gestational age 
pregnancies. Ultrasound in Obstetrics and Gynecology Jan 2007;29(1):52-57. 
96. Vasapollo B, Valensise H, Novelli GP, Altomare F, Galantes A, Arduini D.  
Abnormal maternal cardiac function preceeds the clinical manifestation of fetal 
growth restriction. Ultrasound Obstet Gynecol 2004;24:23–29. 
97. Rey E. Effects of methyldopa on umbilical and placental artery blood flow velocity 
waveforms. Obstet Gynecol. 1992 Nov; 80(5)783-7. 
98. Ganzevoort W, Rep A, Bonsel G, De Vries JI, Wolf H, PETRA Investigators. A 
randomised trial of plasma volume expansion in hypertensive disorders of 
pregnancy: influence on the pulsatility indices of the fetal umbilical artery and 
middle cerebral artery. Am J Obstet Gynecol. 2005 Jan; 192(1):233-9. 
99. Boito S, Struijk P, Pop G, Visser W, Steegers EA, Wladimiroff JW. The impact of 
maternal plasma volume expansion and antihypertensive treatment with 
intravenous dihydrallazine on fetal and maternal haemodynamics during pre-
eclampsia: a clinical, echo-Doppler and viscometric study. Ultrasound Obstet 
Gynecol. 2004 Apr; 23(4):327-32 
100. Walker J, Mathers A, Bjornsson S, Cameron AD, Fairlie FM. The effect of acute 
and chronic hypertensive therapy on maternal and fetoplacental Doppler 
velocimetry. Am J Obstet Gynecol. 2005 Jan; 192(1):258-261. 
101. Visser W and Wallenburg HC. A comparison between the hemodynamic effects 
of oral nifedipine and intravenous dihydrallazine in patients with severe pre-
eclampsia. J Hypertens 1995; 13: 791-795. 
Page | 65  
 
 
102. Qiao F, Wen L, Xu J. Uteroplacental blood flow monitoring by colour Doppler 
flow imaging in pregnancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi. 1995 
Jun; 30(6):337-9. 
103. Soydemir F, Kenny L. Hypertension in pregnancy. Journal of current obstetrics 
and gynaecology (2006) 16, 315-320. 
104. Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for 
cardiovascular disease. Nature. 2007; 3:613–622. 
105. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after 
maternal placental syndromes (CHAMPS): population-based retrospective cohort 
study. Lancet. 2005; 366:1797–1803.  
106. Waldemar A. Carlo. High Risk Pregnancies. Chapter 89. Kliegman: Nelson 
Textbook of Pediatrics, nineteenth edition. Saunders.  
107. Carroll B, Von Ramm O. Fundamentals of current Doppler technology. 
Ultrasound Quarterly 1988; 6(4):275-298. 
108. Roberto M. Lang, Michelle Bierig, Richard B, et al. Recommendations for 
chamber quantification. Eur J Echocardiography (2006) Pg 79-108. 
109. National Committee for Clinical Laboratory Standards. Procedure for handling 
and processing of blood specimens; second edition; approved guidelines. NCCLS 
Document H18-A2; Wayne (PA): NCCLS; 1999 Oct: pg40. 
110. Palmer P. Manual of Diagnostic Ultrasound 1995 Chapter 1:5-9. World Health 
Organisation, World Federation for ultrasound in Medicine and Biology. 
111. Palmer P. Manual of Diagnostic Ultrasound 1995 Chapter 17:237-241. World 
Health Organisation, World Federation for ultrasound in Medicine and Biology. 
112. Claudio Borghio, Daniela Degli Esposti, Vincenzo Immordino, et al. Relationship 
of systemic hemodynamics, left ventricular structure and function, and plasma 
natriuretic peptide concentrations during pregnancy complicated by pre-eclampsia. 
Am J Obstet Gynecol July 2000. Vol 183: 140-7. 
113. Goodwin A, Mercer B. Does maternal race or ethnicity affect the expression of 
severe pre-eclampsia? Am J Obstet Gynecol 2005; 193 (Suppl): 973-978. 
Page | 66  
 
 
114. Knuist M, Bonsel G, Zondervan H, Treffers P. Risk factors for pre-eclampsia in 
nulliparous women in distinct ethnic groups: a prospective cohort study Obstet 
Gynecol 1998; 92: 174-178. 
115. Sanderson JE. Heart failure with a normal ejection fraction. Heart 2007 
February;93(2):155-158. 
116. Smith JC, Miene YH, Fisher MS, et al. Evaluating ventricular function with B-type 
natriuretic peptide in obstetric patients.  Reprod Med. 2005 Mar; 50(3):147-54. 
117. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in 
cardiovascular disease. Lancet 2003; 362: 316-322. 
118. Torbjorn Omland, Asbjorn Aakvaag, Vernon VS Bonarjee, et al. Plasma Brain 
Natriuretic Peptide as an indicator of left ventricular systolic function and long term 
survival after acute myocardial infarction. Circulation 1996; 93:1963-1969. 
119. Fleming SM, O’ Byrne L, Grimes H, et al. Amino terminal pro brain natriuretic 
peptide in normal and hypertensive pregnancy. Hypertens Pregnancy 2001; 20:   
169-175. 
120. Tihtonen KM, Kooobi T, Vuolteenano O, et al. Natriuretic peptides and 
haemodynamics in pre-eclampics.  Am J Obstet Gynecol. 2007; 196(4):328-335. 
121. Frantz MB, Andreas M, Schiess B, et al. NT-pro BNP is increased healthy 
pregnant pregnancies compared to non pregnant controls. Acta Obstet Gynecol 
Scand 2009; 88: 234-237. 
122. Kale A, Kale E, Yalinkaya A, Akendeniz N, et al. The comparison of amino 
terminal proban natriuretic peptide levels in pre-eclamptic and normotensive 
pregnancy. J Perinat Med 2005;33: 121-124. 
123. Irgens HU, Beisaeter I, Irgens LM, Lie RT. Long term mortality of mothers and 
fathers after pre-eclampsia: population based cohort study Br Med J 2001; 323:  
1213-1217. 
124. Shah DM. Pre-eclampsia: new insights. Curr Opin Nephrol Hypertens 2007; 16: 
213-220. 
125. Robert E Hobbs, Roger M Mills. Endogenous B-type Natriuretic Peptide: A limb 
of the regulatory response to acutely decompensated heart failure. Clin 
Cardiol.2008; 31;9:407-412(2008). 
Page | 67  
 
 
126. Cacciapuoti Federico. Natriuretic Peptide system and cardiovascular disease. 
Heart view. 2010 Mar-May;11(1)-15. 
127. Hameed AB, Chan K, Ghamsary M, Elkayam U. Longitudinal changes in the B-
type natriuretic peptide levels in normal pregnancy and postpartum. Clin Cardiol. 
2009 Aug;32(8):E60-2. 
128. Hawfield A, Freedman BI. Pre-eclampsia : the pivotal role of the placenta in its -
pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis 2009; 
3(1): 65-73. 
129. Ruhle W, Ertan A, Gnirs J, et al. Doppler ultrasound in obstetrics-contribution to 
understanding reverse flow in the umbilical artery. Ultraschall Med. 1991 Jun; 12 (3): 
134-8. 
130. Spinillo A, Bergante C, Gardella B, Mainini R, Montanari L. Interaction between 
risk factors for fetal growth retardation associated with abnormal umbilical artery 
Doppler studies. Acta Obstet Gynecol Scand. 2004 May; 83(5):431-5. 
131. Joern H, Rath W. Comparison of Doppler sonographic examinations of the 
umbilical and uterine arteries in high risk pregnancies. Fetal Diagn Ther. 1998 May-
Jun; 13(3):150-3. 
132. Arauz J, Leon J, Velasquez P, Jimenez G, Perez C. Umbilical artery Doppler 
velocimetry and adverse perinatal outcomes in Severe Pre-Eclampsia: Ginecol Obstet 
Mex. 2008 Aug; 76(8): 440-9. 
133. Fleischer A, Schilman H, Farmakides G, et al. Umbilical artery waveforms and 
intra-uterine growth retardation. Am J Obstet Gynecol 1985; 151: 502-505. 
134. Giles W, Trudinger B, Baird P. Fetal umbilical artery flow velocity waveforms and 
placental resistance: pathological correlation. Br J Obstet Gynaecol 1987; 157:     
900-902. 
135. Harrington K, Thompson MO, Carpenter RG, Nguyen M, Campbell S. Doppler 
fetal circulation in pregnancies complicated by pre-eclampsia or delivery of a small 
for gestational age baby:  Longitudinal analysis. BJOG. May 1999; 106;5:453-466. 
136. Habli M, Levine RJ, Qian C, Sibai B. Neonatal outcomes in pregnancies with pre-
eclampsia or gestational hypertension and in normotensive pregnancies that 
delivered at 35, 36 or 37 weeks of gestation. Am J Obstet Gynecol. 2007 
Oct;197(4):406.e1-7. 
Page | 68  
 
 
137. Ayaz A, Muhammad T, Hussain SA, Habib S. Neonatal outcomes in pre-eclamptic 
patients. J Ayub Med Coll Abbottabad. 2009 Apr-Jun;21(2):53-55. 
138. Sutton T, Stewart R, Gerber I, et.al. Plasma Natriuretic Peptide levels increase 
with symptoms and severity of mitral regurgitation J Am Coll Card 2003l 41:2280-7. 
139. Bodnar L, Catov J, Klebanoff M, Ness R, Roberts J. Pre-pregnancy body mass 
index and the occurrence of severe hypertensive disorders of pregnancy. 
Epidemiology 2007; 18(2): 234-39. 
 
 




a) INFORMED CONSENT ENGLISH 
Consent to participate in the study 
Study title:  To identify the changes in the haemodynamics in patients with Pre-
Eclampsia using BNP and Doppler studies of the heart and uterine circulation. 
You have been asked to participate in a research study. 
You have been informed about the study by Dr S Fayers. 
You may contact Dr S Fayers at any time if you have questions at (031) 2604250. 
You may contact the Medical Research Office at the Nelson Mandela School of 
Medicine at (031) 2604604 if you have any questions about your rights as a research 
subject. 
Your participation is in this research is voluntary, and you will not be penalized or 
lose any treatment benefits if you refuse to participate or decide to discontinue 
participation. 
Your blood samples will be discarded after the study and will not be used for any 
further tests. 
If you agree to participate, you will be given a signed copy of this document and the 
participant information sheet with the summary of the research. 
The research study including the above information has been described to me 
verbally.  I understand what my involvement in the study means and I voluntarily 
agree to participate. 
 
____________________   ______________ 
Signature of participant    Date 
 
____________________   ______________ 
Signature of witness     Date 
Page | 70  
 
 
b) INFORMED CONSENT (ISIZULU) ISIVUMELWANO 
SOKUBA INGXENYE YOCWANINGO  
 
Isihloko sesifundo  
Ukusetshenziswa kohlobo u-B lwe Natriuretic peptide emazingeni okukhalima isifo 
esenyusa umfutho wegazi ezinyangeni ezintathu zokugcina zokukhulelwa. 
Ucelwe ukuba ube ingxenye esifundweni socwaningo. 
Utsheliwe ngesifundo nguDokotela S Fayers. 
Ungamthinta uDokotela S Fayers nganoma isiphi isikhathi uma unemibuzo ku 
0795047462. 
Ungathintana nehhovisi Lezocwaningo Lwezempilo Esikoleni Sezifundo Zokwelashwa 
i Nelson Mandela ku (031)2604604 uma unemibuzo ngamalungelo onawo 
njengomuntu obambe iqhaza ocwaningweni. 
Ukubamba kwakho iqhaza kulolu cwaningo akuphoqiwe, futhi uma ukhetha 
ukungabi ingxenye yalo angeke ujeziswe noma ulahlekelwe inzuzo yakho 
yokwelashwa uma wenqaba noma uthatha isinqumo sokuyeka. 
Igazi lakho lizolahlwa emva kocwaningo, futhi ngeke lisetshenziselwe okunye 
ukuhlolwa. 
Uma uvuma ukuba ukubamba iqhaza kulolu cwaningo, uzonikezwa isifaniso salo 
mqulu esisayiniwe, nemininingwano yobambe iqhaza ebeka kafuphi ngocwaningo. 
Isifundo socwaningo kubandakanya nolwazi olubhalwe ngenhla kuchazwe kimina 
ngomlomo. Ngiyaqonda ukuthi kuchazani ukuba ingxenye kulolu cwaningo futhi 
ngiyavuma ngokuzikethela ukubamba iqhazao. 
 
____________________   ______________ 
Isignesha yobambe iqhaza     Usuku 
 
____________________   ______________ 
Isignesha kafakazi       Usuku 
